[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 474
1. Saleh S, Lam AK, Ho YH: Real-time PCR quantification of human telomerase reverse transcriptase (hTERT) in colorectal cancer. Pathology; 2008 Jan;40(1):25-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of telomerase activity has not been investigated in a consecutive series of patients with colorectal adenocarcinoma in North Queensland.
  • The objective of this study was to evaluate the significance of hTERT mRNA expression in colorectal adenocarcinoma in North Queensland.
  • METHODS: Matched samples of tumour and adjacent non-tumorous mucosa samples from 53 colorectal carcinomas and nine colorectal adenomas were collected.
  • The level of expression in the colorectal adenocarcinomas was significantly higher than the corresponding non-tumorous mucosa (p = 0.009, t-test).
  • The level of expression in the adenocarcinomas was slightly higher than those of adenomas, but the difference was not statistically significant.
  • A higher level of hTERT expression was often noted in the adenocarcinomas arising from the left colon and rectum when compared with those from the right colon (p = 0.029).
  • CONCLUSIONS: Colorectal adenocarcinoma revealed expression of telomerase hTERT mRNA, which was detected quantitatively by real-time PCR. hTERT could be a potential biomarker for colorectal cancer.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenoma / enzymology. Colorectal Neoplasms / enzymology. Telomerase / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038311.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


2. Nowak M, Madej JA, Dziegiel P: Expression of Breast Cancer Resistance Protein (BCRP-1) in canine mammary adenocarcinomas and adenomas. In Vivo; 2009 Sep-Oct;23(5):705-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Breast Cancer Resistance Protein (BCRP-1) in canine mammary adenocarcinomas and adenomas.
  • Localization and intensity of BCRP-1 expression was evaluated in mammary adenocarcinomas and adenomas in dogs.
  • MATERIALS AND METHODS: Materials for the study were sampled in the course of surgery from 54 dogs, of various breeds, aged 6 to 16 years (36 cases of mammary adenocarcinoma and 18 cases of mammary adenoma).
  • RESULTS: Expression of BCRP-1 was detected in over 85% of adenocarcinomas and almost 28% of adenomas.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Adenocarcinoma / veterinary. Adenoma / veterinary. Mammary Neoplasms, Animal / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779104.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / Biomarkers, Tumor
  •  go-up   go-down


3. Lea IA, Jackson MA, Dunnick JK: Genetic pathways to colorectal cancer. Mutat Res; 2009 Nov 2;670(1-2):96-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The colorectal cancer paradigm explains how genetic and histological changes lead normal epithelial cell to transform into pre-malignant adenomas then progress to malignant carcinomas.
  • Alterations of APC, KRAS and TP53 were observed in a higher percentage of adenocarcinomas compared to adenomas (P<0.05) indicating that the alterations accumulated with malignancy.
  • Mutations (single base substitutions) occurred most frequently at codons 175 and 273 in both tumor types; however, in adenocarcinomas the mutation incidence at codon 248 was approximately three times that reported in adenomas.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1148-59 [18337604.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1493-9 [7731703.001]
  • [Cites] Hum Mol Genet. 2005 Jan 15;14(2):319-26 [15574462.001]
  • [Cites] Front Biosci. 2005;10:1118-34 [15769611.001]
  • [Cites] Biochem Soc Trans. 2005 Aug;33(Pt 4):672-5 [16042571.001]
  • [Cites] Mutat Res. 2005 Dec 30;592(1-2):6-17 [15990124.001]
  • [Cites] Toxicol Sci. 2006 Apr;90(2):400-18 [16410370.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):138-62 [17045745.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):1851-8 [17693665.001]
  • [Cites] Folia Histochem Cytobiol. 2007;45(3):149-58 [17951162.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Carcinogenesis. 2008 Feb;29(2):434-9 [18048385.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • (PMID = 19576232.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / N43ES15477; United States / NIEHS NIH HHS / ES / ES035513; United States / NIEHS NIH HHS / ES / N01 ES035513; United States / Intramural NIH HHS / / ; United States / NIEHS NIH HHS / ES / N43 ES 15477
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS134552; NLM/ PMC2768054
  •  go-up   go-down


Advertisement
4. Gassler N, Herr I, Schneider A, Penzel R, Langbein L, Schirmacher P, Kopitz J: Impaired expression of acyl-CoA synthetase 5 in sporadic colorectal adenocarcinomas. J Pathol; 2005 Nov;207(3):295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired expression of acyl-CoA synthetase 5 in sporadic colorectal adenocarcinomas.
  • In the present study, gene expression, protein synthesis, and enzymatic activity of ACS5 in sporadic colorectal adenocarcinomas, adenomas, and established cell lines were analysed using RT-PCR, western blot analysis, immunofluorescence, and an enzymatic assay.
  • Enhanced expression of ACS5 mRNA and protein as well as enzymatic activity was found in adenomas and in 11 (73%; group 1) of 15 colorectal adenocarcinomas investigated, while a decrease of ACS5 was seen in four tumours (27%; group 2).
  • However, basal ACS5 enzymatic activity was increased as a percentage of the total activity of ACSs in both groups, arguing for an absolute (group 1) or relative (group 2) increase in ACS5 enzymatic activity in all adenocarcinomas investigated.
  • These findings are reflected by in vitro analysis of three established colorectal adenocarcinoma cell lines, in which activity of ACS5 occurred.
  • [MeSH-major] Adenocarcinoma / metabolism. Coenzyme A Ligases / metabolism. Colorectal Neoplasms / metabolism
  • [MeSH-minor] Adenoma / enzymology. Adenoma / genetics. Adenoma / metabolism. Aged. Aged, 80 and over. Cell Line, Tumor. Colon / enzymology. Colon / metabolism. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Intestinal Mucosa / metabolism. Male. Middle Aged. Neoplasm Proteins / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Rectum / enzymology. Rectum / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16110457.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 6.2.1.- / Coenzyme A Ligases; EC 6.2.1.- / acyl CoA synthetase 5
  •  go-up   go-down


5. Nakano M, Wu H, Taura Y, Inoue M: Immunohistochemical detection of Mdm2 and p53 in feline mammary gland tumors. J Vet Med Sci; 2006 May;68(5):421-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to evaluate nuclear reactivity of Mdm2 and p53 proteins by immunohistochemical means in feline mammary gland tumors; 12 adenomas which included 6 adenomatous lesions obtained from the tissue adjacent to adenocarcinomas, and 22 adenocarcinomas.
  • Seven adenomas and 18 adenocarcinomas showed moderate or marked Mdm2 reactivity.
  • Sixteen adenocarcinomas showed moderate to marked p53 reactivity, but 9 adenomas showed none.
  • Discordant Mdm2 overexpression was found in 5 adenomas and 3 adenocarcinomas, although co-overexpression of Mdm2 and p53 was found in 15 adenocarcinomas.
  • Nuclear overexpression of p53 is more frequent in adenocarcinomas, but not in adenomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16757883.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


6. Nowicki MJ, Bishop PR, Subramony C, Wyatt-Ashmead J, May W, Crawford M: Colonic chicken-skin mucosa in children with polyps is not a preneoplastic lesion. J Pediatr Gastroenterol Nutr; 2005 Nov;41(5):600-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chicken-skin mucosa (CSM) is an endoscopic finding initially described associated with adenomatous polyps and adenocarcinoma, suggesting a preneoplastic lesion.
  • To determine whether CSM represents a preneoplastic lesion, we studied endoscopic colonic mucosal biopsies for markers of cell replication (Ki-67) and malignant transformation (p53) in mucosal biopsies of CSM, normal colonic tissue, tubular adenomas, and adenocarcinomas.
  • The degree of Ki-67-positive staining cells was similar for CSM and normal colonic tissue, whereas there was significantly increased staining for both tubular adenomas and adenocarcinomas.
  • There was no evidence of p53 staining in CSM and normal colonic mucosa, whereas there was varying degrees of staining in tubular adenomas and adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / diagnosis. Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / analysis. Biopsy. Child. Child, Preschool. Colon / pathology. Colonoscopy. Female. Humans. Immunohistochemistry. Male. Prospective Studies

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16254516.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


7. Paik SS, Jang SM, Jang KS, Lee KH, Choi D, Jang SJ: Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol; 2009 Feb;16(2):297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma.
  • We investigated leptin expression in normal and neoplastic colorectal tissues and its association with clinicopathological features and clinical outcome in colorectal adenocarcinoma patients.
  • Leptin expression was evaluated on the tissue microarray of 44 normal colon mucosal tissues, 44 adenomatous polyps, and 437 colorectal adenocarcinomas by immunohistochemistry.
  • Frequency of leptin expression was dramatically increased from normal colonic mucosa (2/44, 4.5%) to adenomas (13/44, 29.5%) and adenocarcinomas (321/437, 73.5%) as neoplastic progression.
  • In univariate survival analysis, patients with leptin-positive adenocarcinoma revealed better overall and disease-free survivals (p = 0.032 and p = 0.004, respectively, log-rank test).
  • We conclude that leptin was gradually expressed during the normal-adenoma-adenocarcinoma sequence, suggesting an association in colorectal carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Leptin / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adenomatous Polyps / metabolism. Adenomatous Polyps / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Colon / metabolism. Colon / pathology. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Phenotype. Survival Rate. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050975.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leptin
  •  go-up   go-down


8. Schell AJ, Nickel CJ, Isotalo PA: Complex mucinous cystadenoma of undetermined malignant potential of the urachus. Can Urol Assoc J; 2009 Aug;3(4):E39-E41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urachal mucinous neoplasms are rare and include both villous adenomas and invasive adenocarcinomas.
  • Rarely described in the English literature, mucinous cystadenomas of the urachus should be treated similarly to their villous adenoma counterparts: with complete surgical excision to prevent local tumour recurrences.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672436.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


9. Ball CG, Dupre MP, Falck V, Hui S, Kirkpatrick AW, Gao ZH: Sessile serrated polyp mimicry in patients with solitary rectal ulcer syndrome: is there evidence of preneoplastic change? Arch Pathol Lab Med; 2005 Aug;129(8):1037-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serrated lesions of the colon are divided into conventional hyperplastic polyps and a new set of lesions that are variably called sessile serrated polyps (SSPs) and sessile serrated adenomas.
  • Control tissues included 10 conventional left-sided hyperplastic polyps, 10 right-sided large SSPs, 7 adenocarcinomas with known loss of hMLH1 gene expression, and 4 normal human tonsil tissues.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / complications. Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / metabolism. Carrier Proteins. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Ki-67 Antigen / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Retrospective Studies. Syndrome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048395.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Ki-67 Antigen; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


10. Tsukahara M, Nagai H, Kamiakito T, Kawata H, Takayashiki N, Saito K, Tanaka A: Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas. Pathol Int; 2005 Feb;55(2):63-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of claudin-4 was investigated in human pancreas, pancreatic ductal adenocarcinomas, and intraductal papillary-mucinous tumors of the pancreas (IPMT), and compared with that of claudin-1.
  • Of 12 cases of pancreatic ductal adenocarcinoma, 11 (92%) had positive immunostaining for claudin-4, and seven (58%) for claudin-1.
  • In 44 lesions of 22 cases of IPMT, including six hyperplastic foci distant from the main lesions, clauidin-1 was positive in three out of six (50%) hyperplastic foci, 14 out of 17 (82%) adenomas, three out of 10 (30%) borderline tumors, two out of six (33%) non-invasive carcinomas, and one out of five (20%) invasive carcinomas, producing a statistically negative correlation with histological tumor grades.
  • In contrast, claudin-4 was negative in the six hyperplastic foci, and positive in four out of the 17 (24%) adenomas, five out of the 10 (50%) borderline tumors, five out of the six (83%) non-invasive carcinomas, and four out of the five (80%) invasive carcinomas, producing a statistically positive correlation with histological tumor grades.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Papillary / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Membrane Proteins / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Claudin-1. Claudin-4. Female. Humans. Hyperplasia. Immunohistochemistry. Male. Middle Aged. Pancreas / metabolism. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693851.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


11. Klopfleisch R, Gruber AD: Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands. Res Vet Sci; 2009 Aug;87(1):91-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands.
  • To analyze their role in the malignant progression of canine mammary tumors expression levels of p27 and p21 and its major regulator p53 were compared in simple adenomas, adenocarcinomas of the mammary gland and lymph node metastases with normal mammary gland.
  • Laser microdissection of tissue samples and real-time PCR were used for quantification of mRNA expression levels. p21 was overexpressed in adenocarcinomas, whereas adenomas and metastases expressed p21 more heterogeneously.
  • Comparison of p21 expression in adenocarcinomas and their metastases revealed a significant decrease in expression in metastases.
  • In contrast, p27 expression was reduced in the adenocarcinomas but heterogeneously expressed in adenomas and metastases.
  • [MeSH-major] Adenocarcinoma / veterinary. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Dog Diseases / metabolism. Genes, p53 / physiology. Mammary Neoplasms, Animal / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185891.001).
  • [ISSN] 1532-2661
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / RNA, Messenger; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


12. Scheiden R, Pescatore P, Wagener Y, Kieffer N, Capesius C: Colon cancer in Luxembourg: a national population-based data report, 1988-1998. BMC Cancer; 2005;5:52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to determine a strategy for early detection of colon cancer in the Grand-Duchy of Luxembourg, all consecutive colon adenocarcinomas diagnosed during the period 1988-1998 at a nation-wide level were reviewed.
  • METHODS: The population-based data of the national Morphologic Tumour Registry report all new high-grade adenomas (i.e. high-grade intraepithelial adenomatous neoplasias) and all consecutive new invasive adenocarcinomas of the colon diagnosed in the central department of pathology.
  • RESULTS: Over the study period, 254 new colonic high-grade adenomas and 1379 new invasive adenocarcinomas were found; the crude incidence rates of colon adenocarcinomas grew steadily by 30%.
  • Comparing the two 5-year periods 1988-1992 and 1994-1998, the crude incidence rates of high-grade adenomas (stage 0) rose by 190%, that of stage I cases by 14.3%, stage II cases 12.9% and stage III cases 38.5%, whereas the crude incidence rates of stage IV cases decreased by 11.8%.
  • The high-grade adenoma/adenocarcinoma ratio increased.
  • The right-sided colonic adenocarcinomas in elderly patients (>69 years) increased by 76%.
  • CONCLUSION: The increasing incidence rates of colon adenocarcinomas, the persistence of advanced tumour stages (stage III), the mortality rates which remain stable, and the changing trends in the age- and sub-site distribution underline the need for preventive measures at the age of 50 in asymptomatic patients to reduce mortality from colo(rectal) cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colonic Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 2001 Dec 1;111(8):593-601 [11755501.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2547-54 [11745188.001]
  • [Cites] Oncologist. 2002;7(3):200-4 [12065791.001]
  • [Cites] Gut. 2002 Jul;51(1):60-4 [12077093.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1249-54 [12352244.001]
  • [Cites] Am Surg. 2002 Oct;68(10):871-6 [12412713.001]
  • [Cites] Eur J Cancer Prev. 2002 Dec;11(6):529-34 [12457104.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jan;33(1):38-43 [12604723.001]
  • [Cites] Scand J Surg. 2003;92(1):5-9 [12705545.001]
  • [Cites] An Sist Sanit Navar. 2003 Jan-Apr;26(1):79-97 [12759713.001]
  • [Cites] N Z Med J. 2003 May 16;116(1174):U437 [12766783.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):886-90 [12658426.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10 Suppl):S32-43 [14530656.001]
  • [Cites] Am Surg. 2003 Oct;69(10):866-72 [14570365.001]
  • [Cites] Dig Dis. 2003;21(4):315-9 [14752221.001]
  • [Cites] W V Med J. 2003 Sep-Oct;99(5):182-6 [14959509.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):777-81 [14999789.001]
  • [Cites] Am Surg. 2004 Mar;70(3):259-64 [15055851.001]
  • [Cites] BMC Cancer. 2003 Oct 21;3:27 [14567762.001]
  • [Cites] IARC Sci Publ. 1992;(120):178-861 [1284601.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):12-20 [8115781.001]
  • [Cites] N Engl J Med. 2002 Jun 6;346(23):1781-5 [12050337.001]
  • (PMID = 15913456.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1173094
  •  go-up   go-down


13. Woo VL, Bhuiya T, Kelsch R: Assessment of CD43 expression in adenoid cystic carcinomas, polymorphous low-grade adenocarcinomas, and monomorphic adenomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct;102(4):495-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of CD43 expression in adenoid cystic carcinomas, polymorphous low-grade adenocarcinomas, and monomorphic adenomas.
  • OBJECTIVE: Distinguishing between adenoid cystic carcinoma (ACC), polymorphous low-grade adenocarcinoma (PLGA), and monomorphic adenoma (MA) can occasionally pose a diagnostic challenge.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenoma / diagnosis. Adenoma / metabolism. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997117.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD43; 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Tong GX, Weeden EM, Hamele-Bena D, Huan Y, Unger P, Memeo L, O'Toole K: Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? Am J Surg Pathol; 2008 Sep;32(9):1380-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?
  • Recent evidence has showed that nephrogenic adenoma is a true "nephrogenic" lesion derived from the proliferation of exfoliated and implanted renal tubular cells in the urinary tract, a process that closely resembles the formation of endometriosis.
  • This new concept has led to the identification of renal transcription factor PAX2 as a diagnostic marker for nephrogenic adenoma.
  • In this study, we investigated the expression of PAX8 in nephrogenic adenoma and its mimics.
  • We report here that PAX8 was detected in all nephrogenic adenomas (N=35) and clear cell adenocarcinoma of the lower urinary tract (N=7), but not in prostate adenocarcinoma (N=100), adenocarcinoma (N=9), squamous cell carcinoma (N=5), or urothelial carcinoma (N=48) of the urinary bladder and its variants.
  • PAX2 was also detected in 2 of the 7 clear cell adenocarcinomas of the lower urinary tract.
  • We suggest that PAX8 is an additional marker for identifying nephrogenic adenoma.
  • Expression of PAX8 or PAX2 in both nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract may indicate a possible related tissue origin for these 2 lesions; both may be derived from proliferating renal tubular cells in the urinary tract.
  • In addition, detection of PAX8 or PAX2 in clear cell adenocarcinoma of the lower urinary tract is helpful in differentiating it from urothelial carcinoma and its variants and adenocarcinomas of the urinary bladder or of the prostate.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenoma / metabolism. Biomarkers, Tumor / analysis. Paired Box Transcription Factors / biosynthesis. Urologic Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670350.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


15. Colvin M, Delis A, Bracamonte E, Villar H, Leon LR Jr: Infiltrating adenocarcinoma arising in a villous adenoma of the anal canal. World J Gastroenterol; 2009 Jul 28;15(28):3560-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating adenocarcinoma arising in a villous adenoma of the anal canal.
  • In particular, adenomas and adenocarcinomas are distinctly rare entities in this region.
  • We describe an infiltrating, well-differentiated adenocarcinoma arising in a villous adenoma from the distal anal canal, in an otherwise healthy patient at low risk for gastrointestinal malignancy.
  • Microscopic evaluation revealed an infiltrating well-differentiated adenocarcinoma, arising from a villous adenoma.
  • Our report is the first describing the possible malignant degeneration of a villous adenoma in the anal canal.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Anal Canal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2000 Aug;66(8):789-92 [10966042.001]
  • [Cites] Colorectal Dis. 2008 Jul;10(6):621-3 [17949443.001]
  • [Cites] Histopathology. 2002 Mar;40(3):302-4 [11895502.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1320-4 [14530668.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):249-62 [15137955.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Br J Surg. 1994 Apr;81(4):500-8 [8205420.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] World J Gastroenterol. 2006 Mar 21;12(11):1780-1 [16586552.001]
  • [Cites] Colorectal Dis. 2006 May;8(4):296-301 [16630233.001]
  • [Cites] Eur J Dermatol. 2006 Sep-Oct;16(5):576-8 [17101482.001]
  • [Cites] World J Gastroenterol. 2006 Dec 7;12(45):7304-8 [17143945.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(12):1977-9 [17212165.001]
  • [Cites] Oncologist. 2007 May;12(5):524-34 [17522240.001]
  • [Cites] Surg Today. 2007;37(7):596-9 [17593481.001]
  • [Cites] Tech Coloproctol. 2007 Dec;11(4):340-2 [18060528.001]
  • [Cites] J Am Osteopath Assoc. 2001 Aug;101(8):450-3 [11526879.001]
  • (PMID = 19630115.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2715986
  •  go-up   go-down


16. Moshitch-Moshkovitz S, Tsarfaty G, Kaufman DW, Stein GY, Shichrur K, Solomon E, Sigler RH, Resau JH, Vande Woude GF, Tsarfaty I: In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met. Neoplasia; 2006 May;8(5):353-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-two percent of males spontaneously developed adenomas, adenocarcinomas, and angiosarcomas in their lower abdominal sebaceous glands.
  • Approximately 70% of adenocarcinoma tumors metastasized to the kidneys, lungs, or liver.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Biol. 2001;2(9):REVIEWS1024 [11574061.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):589-96 [11809714.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1642-7 [11920523.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):289-300 [12001990.001]
  • [Cites] Neoplasia. 2002 Nov-Dec;4(6):510-22 [12407445.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):498-505 [12492492.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7166-9 [12499251.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):231-5 [12539177.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1101-5 [12615728.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):135-41 [12705634.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):112-8 [12708484.001]
  • [Cites] Mol Ther. 2003 Jun;7(6):765-73 [12788650.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6272-81 [14559814.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17198-203 [15557554.001]
  • [Cites] Prostate. 2005 Jul 1;64(2):139-48 [15678502.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6190-7 [16144920.001]
  • [Cites] Oncogene. 2003 Nov 20;22(52):8498-508 [14627990.001]
  • [Cites] Anal Quant Cytol Histol. 1999 Oct;21(5):397-408 [10560522.001]
  • [Cites] FASEB J. 2000 Feb;14(2):319-32 [10657988.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 16;272(3):900-5 [10860849.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):365-77 [11005571.001]
  • [Cites] Cytometry. 2000 Nov 1;41(3):155-65 [11042611.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):7-11 [11191066.001]
  • [Cites] Histochem Cell Biol. 2001 Jan;115(1):49-58 [11219608.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):1023-34 [11381087.001]
  • [Cites] Int J Androl. 2001 Oct;24(5):300-5 [11554988.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):202-11 [14734471.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):533-40 [15277227.001]
  • [Cites] Exp Cell Res. 2004 Sep 10;299(1):248-56 [15302591.001]
  • [Cites] Mol Carcinog. 2004 Nov;41(3):150-63 [15390081.001]
  • [Cites] Mol Cell Biol. 1990 Aug;10(8):4406-11 [2164640.001]
  • [Cites] Cancer Metastasis Rev. 1991 Oct;10(3):217-27 [1662559.001]
  • [Cites] Oncogene. 1992 Jun;7(6):1149-57 [1317541.001]
  • [Cites] Mol Cell Biol. 1992 Nov;12(11):5152-8 [1406687.001]
  • [Cites] Acta Pathol Jpn. 1992 Aug;42(8):585-94 [1360186.001]
  • [Cites] Cell Growth Differ. 1993 Jul;4(7):563-9 [8398896.001]
  • [Cites] Science. 1994 Jan 7;263(5143):98-101 [7505952.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1630-3 [8137271.001]
  • [Cites] J Biol Chem. 1994 Apr 29;269(17):12846-51 [8175699.001]
  • [Cites] Cell Growth Differ. 1996 Nov;7(11):1513-23 [8930401.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6 [9012848.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):749-60 [9024713.001]
  • [Cites] Nat Genet. 1997 May;16(1):68-73 [9140397.001]
  • [Cites] FEBS Lett. 1997 May 5;407(3):313-9 [9175875.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5391-8 [9393765.001]
  • [Cites] Ophthalmology. 1998 Mar;105(3):497-506 [9499782.001]
  • [Cites] Biochim Biophys Acta. 1998 Feb 11;1395(3):252-8 [9512656.001]
  • [Cites] Cancer. 1998 Apr 15;82(8):1513-20 [9554529.001]
  • [Cites] Exp Cell Res. 1998 Oct 10;244(1):367-9 [9770380.001]
  • [Cites] Pathol Int. 1998 Oct;48(10):757-62 [9788258.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5157-67 [9823327.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14417-22 [9826715.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):887-95 [10023664.001]
  • [Cites] Endocr J. 1999 Jun;46(3):359-66 [10503987.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):678-82 [15455388.001]
  • (PMID = 16790084.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA093990; United States / NCI NIH HHS / CA / P50CA93990
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  • [Other-IDs] NLM/ PMC1592452
  •  go-up   go-down


17. Sen M, Ozdemir O, Turan M, Arici S, Yildiz F, Koksal B, Goze F: Epigenetic inactivation of tumor suppressor SFRP2 and point mutation in KRAS proto-oncogene in fistula-associated mucinous type anal adenocarcinoma: report of two cases. Intern Med; 2010;49(15):1637-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic inactivation of tumor suppressor SFRP2 and point mutation in KRAS proto-oncogene in fistula-associated mucinous type anal adenocarcinoma: report of two cases.
  • The secreted frizzled-related proteins (SFRPs) genes are unmethylated in normal colorectal mucosa tissue but aberrant methylation profiles can be detected in colorectal cancer (CRC), adenomas, and in aberrant crypt foci.
  • The aim of the current study was to clarify whether SFRP2 methylation and K-ras structural mutation in fecal DNA can be found in stool and tumoral tissues of individuals with fistula-associated mucinous type anal adenocarcinomas (MTAA).Two man patients (68 and 56 years old) were treated for anorectal fistula in the surgical department.
  • The current results showed that the combined effects of somatic mutations in K-ras and epigenetic alterations in SFRP2 genes may play an active role in the development of mucinous type anal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Anus Neoplasms / genetics. Membrane Proteins / genetics. Point Mutation / genetics. Proto-Oncogene Proteins / genetics. Rectal Fistula / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686305.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / SFRP2 protein, human; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


18. Nassar H, Albores-Saavedra J, Klimstra DS: High-grade neuroendocrine carcinoma of the ampulla of vater: a clinicopathologic and immunohistochemical analysis of 14 cases. Am J Surg Pathol; 2005 May;29(5):588-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunohistochemical findings were compared with those of 13 cases of primary poorly differentiated ampullary adenocarcinomas (PDACA) lacking neuroendocrine morphology.
  • Half of the tumors were associated with adenomas of the adjacent mucosa, 2 with high-grade dysplasia.
  • Two HGNECs were combined with a conventional adenocarcinoma and another with a squamous cell carcinoma component.
  • The clinical course parallels that of their pulmonary counterparts and appears to be worse than that of locally advanced ampullary adenocarcinomas.
  • The association with adenoma and or conventional adenocarcinoma components may suggest a common pathway in the initial carcinogenesis of these two types of tumors.
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832081.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


19. Hornick JL, Lauwers GY, Odze RD: Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol; 2005 Mar;29(3):381-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
  • Not uncommonly, bile duct adenomas (BDAs) and hamartomas (BDHs) of the liver may be difficult to distinguish from metastatic well-differentiated ductal adenocarcinoma of the pancreas.
  • The primary purpose of this study was to determine if a panel of immunohistochemical stains can help distinguish BDA or BDH from metastatic pancreatic adenocarcinoma in the liver.
  • Routinely processed tissue sections from 25 BDA, 10 BDH, 25 metastatic pancreatic adenocarcinomas to the liver and 6 cases each of metastatic colorectal, breast, and lung adenocarcinomas were immunohistochemically stained for CK7, CK8/CK18, CK19, CK20, p53, p63, TAG-72, monoclonal CEA (mCEA), polyclonal CEA (pCEA), HER-2/neu, AMACR (alpha-methylacyl-CoA racemase), Dpc4 (Smad4), and mesothelin.
  • Significantly more (P < 0.05) metastatic pancreatic adenocarcinomas were positive for CK20 (76%), p53 (60%), TAG-72 (88%), mCEA (92%), HER2/neu (40%), and mesothelin (64%) and showed loss of Dpc4 (44%), in comparison to BDA (CK20, 40%; p53, 0%; TAG-72, 0%; mCEA, 0%; HER2/neu, 12%; mesothelin, 0%; loss of Dpc4, 0%) or BDH (CK20, 10%; p53, 0%; TAG-72, 0%; mCEA, 10%; HER2/neu, 0%; mesothelin, 0%; loss of Dpc4, 0%).
  • Of these antibodies, p53, TAG-72, mCEA, loss of Dpc4, and mesothelin had the highest specificity for pancreatic adenocarcinoma, with mCEA having the highest sensitivity (92%).
  • Although none of the BDA or BDH was positive for either p63 or AMACR, two of the metastatic pancreatic adenocarcinomas (8%) were positive for each of these peptides (P > 0.05).
  • For nonpancreatic adenocarcinomas, mCEA showed a reasonably high sensitivity and 100% specificity in the differential diagnosis versus BDA.
  • Immunohistochemical expression of p53, TAG-72, mCEA, mesothelin, and loss of Dpc4 can help distinguish metastatic pancreatic adenocarcinoma in the liver from BDA or BDH.
  • Although p63 and AMACR are also specific for pancreatic adenocarcinoma, their low sensitivity limits their use in clinical practice.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma / pathology. Bile Duct Neoplasms / pathology. Hamartoma / pathology. Liver Diseases / pathology. Pancreatic Neoplasms / pathology


20. Ohara T, Morishita T, Suzuki H, Hibi T: Heterozygous Thr 135 Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of toll-like receptor 4 in patients with poorly-differentiated gastric adenocarcinomas. Int J Mol Med; 2006 Jul;18(1):59-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterozygous Thr 135 Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of toll-like receptor 4 in patients with poorly-differentiated gastric adenocarcinomas.
  • Of these, 22 had well-differentiated and 20 had poorly-differentiated adenocarcinomas, the latter group including 10 with signet ring cell carcinomas.
  • The remaining 6 had gastric adenomas.
  • None of the healthy volunteers, patients with gastric adenomas or those with well-differentiated gastric adenocarcinomas showed mutations.
  • However, 8 of the 20 with poorly-differentiated gastric adenocarcinoma showed heterozygosity at the 135th position of the amino acid sequence of TLR4, and a mutation from threonine to alanine was found at this site.
  • This suggests a disturbance in the protein phosphorylation reaction of TLR4, and that this disturbance is related to the development of poorly-differentiated gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Polymorphism, Genetic / genetics. Stomach Neoplasms / genetics. Toll-Like Receptor 4 / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786156.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Toll-Like Receptor 2; 0 / Toll-Like Receptor 4; 0 / Toll-Like Receptor 6; 0 / Toll-Like Receptor 9; 0 / Toll-Like Receptors
  •  go-up   go-down


21. Morton D, Bailey KL, Stout CL, Weaver RJ, White KA, Lorenzen MJ, Ball DJ: N-Methyl-N-Nitrosourea (MNU): A positive control chemical for p53+/- mouse carcinogenicity studies. Toxicol Pathol; 2008 Dec;36(7):926-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine males and five females treated with MNU had adenomas or adenocarcinomas of the small intestine, whereas no intestinal neoplasms were observed in control mice.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Adenoma / chemically induced. Adenoma / pathology. Animals. Antigens, CD3 / metabolism. Duodenal Neoplasms / chemically induced. Duodenal Neoplasms / pathology. Female. Genes, p53. Heterozygote. Injections, Intraperitoneal. Intestine, Small / pathology. Jejunal Neoplasms / chemically induced. Jejunal Neoplasms / pathology. Lymphoma / chemically induced. Lymphoma / pathology. Male. Mice. Mice, Knockout. Thymus Gland / pathology. Thymus Neoplasms / chemically induced. Thymus Neoplasms / pathology

  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827072.001).
  • [ISSN] 1533-1601
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Carcinogens; 684-93-5 / Methylnitrosourea
  •  go-up   go-down


22. Aranha MM, Borralho PM, Ravasco P, Moreira da Silva IB, Correia L, Fernandes A, Camilo ME, Rodrigues CM: NF-kappaB and apoptosis in colorectal tumourigenesis. Eur J Clin Invest; 2007 May;37(5):416-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Apoptosis was evaluated by the TUNEL assay in 48 patient samples, including adenomas, adenocarcinomas and adjacent normal mucosas.
  • CONCLUSIONS: NF-kappaB expression and apoptosis are increased from adenoma to poorly differentiated adenocarcinoma tissues.
  • [MeSH-major] Adenoma / physiopathology. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / physiopathology. NF-kappa B / metabolism. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17461988.001).
  • [ISSN] 0014-2972
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NF-kappa B; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein
  •  go-up   go-down


23. Gui X, Guzman G, Dobner PR, Kadkol SS: Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma. Peptides; 2008 Sep;29(9):1609-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma.
  • NT is expressed in fetal but not differentiated colonic epithelium and is re-expressed in colonic adenocarcinoma.
  • To further understand the possible role of NTSR1 expression in colonic tumorigenesis and progression, we examined NTSR1 mRNA by in situ hybridization in normal colonic mucosa, adenomas, and colonic adenocarcinomas.
  • NTSR1 mRNA expression was undetectable or weak in superficial differentiated epithelial cells of normal colonic epithelium, but adenomas and adenocarcinomas showed moderate to strong expression (p<0.05).
  • Adenocarcinomas showed a higher level of expression compared to adenomas (p<0.05).
  • Furthermore, adenocarcinomas that infiltrated into and beyond the muscularis propria showed a higher intensity of NTSR1 expression compared with tumors that were localized to the mucosa or submucosa.
  • These results suggest that increased NTSR1 expression may be an early event during colonic tumorigenesis and also contribute to tumor progression and aggressive behavior in colonic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Receptors, Neurotensin / biosynthesis

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541341.001).
  • [ISSN] 0196-9781
  • [Journal-full-title] Peptides
  • [ISO-abbreviation] Peptides
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Neurotensin; 0 / neurotensin type 1 receptor
  •  go-up   go-down


24. Chang HK, Yu E, Kim J, Bae YK, Jang KT, Jung ES, Yoon GS, Kim JM, Oh YH, Bae HI, Kim GI, Jung SJ, Gu MJ, Kim JY, Jang KY, Jun SY, Eom DW, Kwon KW, Kang GH, Park JB, Hong S, Lee JS, Park JY, Hong SM, Korean Small Intestinal Cancer Study Group: Adenocarcinoma of the small intestine: a multi-institutional study of 197 surgically resected cases. Hum Pathol; 2010 Aug;41(8):1087-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the small intestine: a multi-institutional study of 197 surgically resected cases.
  • Small intestinal adenocarcinoma is a rare malignant neoplasm, and its clinicopathologic characteristics have not been well elucidated.
  • A total of 197 small intestinal adenocarcinoma cases were collected from 22 institutions in South Korea and were evaluated for clinicopathologic factors that affect the prognosis of small intestinal adenocarcinoma patients using univariate and multivariate analyses.
  • Predisposing conditions were observed in 23 cases (12%), including 17 cases with sporadic adenomas, 3 with Peutz-Jeghers syndrome, 2 with Meckel diverticulum, and 1 with Crohn disease.
  • The median survival time for all small intestinal adenocarcinoma patients was 39.7 months.
  • Compared with small intestinal adenocarcinomas without accompanying sporadic adenomas, small intestinal adenocarcinomas with accompanying adenomas were more well differentiated (P < .0001), with a more polypoid growth pattern (P < .0001), a lower pT classification (P < .0001), less perineural invasion (P = .01), and less lymphatic invasion (P = .03).
  • Small intestinal adenocarcinoma patients with associated sporadic adenomas (77%) had a significantly better 5-year survival rate than those without sporadic adenomas (38%, P = .02).
  • By univariate analysis, small intestinal adenocarcinoma patients had significantly different survival based on pT classification (P = .003), lymph node metastasis (P < .0001), distal location (jejunal and ileal carcinomas) (P = .003), retroperitoneal tumor seeding (P < .0001), vascular invasion (P = .007), lymphatic invasion (P = .001), peritumoral dysplasia (P = .004), and radiation therapy (P = .006).
  • In conclusion, (1) small intestinal adenocarcinomas are diagnosed at an advanced disease stage; therefore, the development of strategies for detection at an earlier stage is needed. (2) Small intestinal adenocarcinoma patients with an adenomatous component had a better survival than those without an adenomatous component. (3) Lymph node metastasis and distal location (jejunum and ileum) of tumor are the most important independent prognostic factors.
  • [MeSH-major] Adenocarcinoma / pathology. Duodenal Neoplasms / pathology. Ileal Neoplasms / pathology. Jejunal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20334897.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Dance-Barnes ST, Kock ND, Moore JE, Lin EY, Mosley LJ, D'Agostino RB Jr, McCoy TP, Townsend AJ, Miller MS: Lung tumor promotion by curcumin. Carcinogenesis; 2009 Jun;30(6):1016-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopic examination showed that the percentage of lung lesions that were adenomas and adenocarcinomas increased to 66% in DOX/BHT, 66% in DOX/curcumin and 49% in DOX/BHT/curcumin-treated groups relative to DOX only treated mice (19%).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2,6-DI-T-BUTYL-P-CRESOL .
  • Hazardous Substances Data Bank. CURCUMIN .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AAPS J. 2006;8(3):E443-9 [17025261.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):950-2 [16943408.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3423-30 [17545551.001]
  • [Cites] Biochem Pharmacol. 2008 Feb 15;75(4):787-809 [17900536.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):1022-32 [18321868.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Aug 15;231(1):77-84 [18565564.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11105-9 [18678913.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):6013-20 [10557090.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11858-64 [10766812.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Sep;279(3):L452-9 [10956619.001]
  • [Cites] Exp Lung Res. 2001 Apr-May;27(3):197-216 [11293324.001]
  • [Cites] Toxicology. 2001 Dec 1;169(1):1-15 [11696405.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):2895-900 [11712783.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):105-11 [11815407.001]
  • [Cites] Prostate. 2002 May 15;51(3):211-8 [11967955.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):535-40 [12050094.001]
  • [Cites] Toxicology. 2002 Aug 1;177(1):91-104 [12126798.001]
  • [Cites] Arch Biochem Biophys. 2002 Sep 15;405(2):223-30 [12220536.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):363-98 [12680238.001]
  • [Cites] J Postgrad Med. 2003 Jul-Sep;49(3):222-8 [14597785.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):45-52 [15179623.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1611-7 [15090465.001]
  • [Cites] J Natl Cancer Inst. 1977 Feb;58(2):301-5 [833878.001]
  • [Cites] Acta Pharmacol Toxicol (Copenh). 1978 Aug;43(2):86-92 [696348.001]
  • [Cites] Toxicology. 1980;16(3):259-65 [7423534.001]
  • [Cites] Drug Metab Rev. 1981;12(2):325-37 [7040018.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):5941-6 [3139287.001]
  • [Cites] Planta Med. 1991 Feb;57(1):1-7 [2062949.001]
  • [Cites] Anticancer Drugs. 1991 Feb;2(1):79-86 [1958856.001]
  • [Cites] Cancer Lett. 1992 Jun 15;64(2):117-21 [1611594.001]
  • [Cites] Carcinogenesis. 1992 Nov;13(11):2183-6 [1423891.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):24995-5000 [7559628.001]
  • [Cites] N Engl J Med. 1996 May 2;334(18):1150-5 [8602180.001]
  • [Cites] Cancer Lett. 1996 Jun 5;103(2):137-41 [8635149.001]
  • [Cites] Carcinogenesis. 1997 Mar;18(3):491-6 [9067547.001]
  • [Cites] Carcinogenesis. 1997 May;18(5):1001-6 [9163687.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 1;55(7):965-73 [9605420.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):597-601 [9973206.001]
  • [Cites] Carcinogenesis. 1999 Jun;20(6):1011-8 [10357781.001]
  • [Cites] Cancer Lett. 1999 Apr 1;137(2):123-30 [10374832.001]
  • [Cites] Indian J Gastroenterol. 1999 Jul-Sep;18(3):118-21 [10407566.001]
  • [Cites] Am J Clin Nutr. 2005 Jan;81(1 Suppl):284S-291S [15640492.001]
  • [Cites] Cancer Lett. 2005 Jun 8;223(2):181-90 [15896452.001]
  • [Cites] Bioorg Med Chem Lett. 2005 Jun 2;15(11):2738-44 [15878268.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(13):1955-68 [16081279.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6738-44 [16166455.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2196-206 [16051643.001]
  • [Cites] Antioxid Redox Signal. 2005 Nov-Dec;7(11-12):1728-39 [16356133.001]
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1128-33 [16418177.001]
  • [Cites] Mol Carcinog. 2006 Jul;45(7):506-17 [16482519.001]
  • [Cites] Food Chem Toxicol. 2006 Sep;44(9):1443-8 [16814915.001]
  • [ErratumIn] Carcinogenesis. 2010 Oct;31(10):1903. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text
  • (PMID = 19359593.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA91909; United States / NCI NIH HHS / CA / CA91909-S1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Reactive Oxygen Species; 184SNS8VUH / Sulindac; 1P9D0Z171K / Butylated Hydroxytoluene; IT942ZTH98 / Curcumin; N12000U13O / Doxycycline
  • [Other-IDs] NLM/ PMC2691137
  •  go-up   go-down


26. Ribeiro da Rocha JJ, Féres O: A new proctoscope for transanal endoscopic operations. Tech Coloproctol; 2008 Sep;12(3):241-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In operations utilizing this proctoscope, 17 adenomas, 25 adenocarcinomas, 1 carcinoid and 1 endometrioma were excised.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Proctoscopes. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Colorectal Cancer. 2005 Nov;5(4):268-73 [16356304.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):207-10 [8689164.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1167-72 [15154642.001]
  • [Cites] Surg Laparosc Endosc. 1998 Apr;8(2):117-9 [9566564.001]
  • [Cites] Isr Med Assoc J. 2005 Jul;7(7):435-8 [16011058.001]
  • [Cites] Chirurg. 1996 Feb;67(2):121-8 [8881207.001]
  • [Cites] Endoscopy. 1987 Nov;19 Suppl 1:38-42 [3428240.001]
  • [Cites] World J Surg. 2001 Jul;25(7):870-5 [11572026.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1233-7 [7577029.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Jul;5(3):723-34 [8829329.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Praxis (Bern 1994). 1998 Aug 12;87(33):1014-8 [9747130.001]
  • [Cites] Recent Results Cancer Res. 2005;165:120-35 [15865027.001]
  • [Cites] Surg Endosc. 2003 Sep;17(9):1461-3 [12739115.001]
  • [Cites] Proc R Soc Med. 1970;63 Suppl:91-4 [4947872.001]
  • [Cites] Colorectal Dis. 2000 Jan;2(1):13-7 [23577928.001]
  • [Cites] Colorectal Dis. 2005 Mar;7(2):133-7 [15720349.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Jul;10(3):709-31, xi [11685937.001]
  • [Cites] Dig Surg. 2005;22(3):182-9; discussion 189-90 [16137996.001]
  • [Cites] J Surg Oncol. 2000 Jun;74(2):158-62 [10914828.001]
  • [Cites] ANZ J Surg. 2002 Dec;72(12):854-6 [12485218.001]
  • [Cites] Surg Endosc. 1996 Jul;10(7):736-41 [8662430.001]
  • [Cites] World J Surg. 2003 Feb;27(2):197-202 [12616436.001]
  • [Cites] Surg Endosc. 1998 Feb;12(2):151-3 [9479731.001]
  • [Cites] Surg Endosc. 1988;2(4):245-50 [3071872.001]
  • [Cites] Surg Endosc. 1999 Jul;13(7):710-2 [10384080.001]
  • [Cites] Chirurg. 1996 Feb;67(2):139-44 [8881210.001]
  • [Cites] Semin Surg Oncol. 2000 Dec;19(4):367-75 [11241919.001]
  • [Cites] Colorectal Dis. 2004 Sep;6(5):350-5 [15335369.001]
  • [Cites] Colorectal Dis. 2002 Nov;4(6):467-72 [12790922.001]
  • [Cites] Dis Colon Rectum. 1986 Jun;29(6):374-7 [3709314.001]
  • [Cites] Hong Kong Med J. 2004 Aug;10(4):239-43 [15299168.001]
  • [Cites] Am J Surg. 1997 May;173(5):383-5 [9168071.001]
  • [Cites] Schweiz Med Wochenschr. 1994 Oct 15;124(41):1800-6 [7973506.001]
  • [Cites] Br J Surg. 2002 Jun;89(6):769-74 [12027989.001]
  • [Cites] Colorectal Dis. 2000 Apr;2(2):73-6 [23577988.001]
  • [Cites] Semin Laparosc Surg. 2004 Mar;11(1):45-51 [15094978.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1193-9 [7587763.001]
  • [Cites] Surg Endosc. 1988;2(1):24-7 [3175831.001]
  • [Cites] Colorectal Dis. 2003 Mar;5(2):159-63 [12780906.001]
  • [Cites] Dig Surg. 2005;22(1-2):6-15 [15761225.001]
  • [Cites] CA Cancer J Clin. 1997 Mar-Apr;47(2):113-28 [9074489.001]
  • (PMID = 18679568.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


27. Witschi H: The complexities of an apparently simple lung tumor model: The A/J mouse. Exp Toxicol Pathol; 2005 Jul;57 Suppl 1:171-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the end of the experiment, the mice are 1-year old and about 80% of the tumors are adenomas, the remainder adenomas with carcinomatous foci or adenocarcinomas.
  • Tobacco smoke does not increase the percentage of adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / chemically induced. Adenoma / chemically induced. Disease Models, Animal. Lung Neoplasms / chemically induced. Tobacco Smoke Pollution / adverse effects

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Secondhand Smoke.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092725.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA96217; United States / NIEHS NIH HHS / ES / ES05707; United States / NIEHS NIH HHS / ES / ES07499
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tobacco Smoke Pollution
  • [Number-of-references] 62
  •  go-up   go-down


28. Lee SA, Choi SR, Jang JS, Lee JH, Roh MH, Kim SO, Kim MC, Kim SJ, Jeong JS: Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection. Dig Dis Sci; 2010 Jul;55(7):1955-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection.
  • Despite recent medical advancements, gastric adenoma or adenocarcinoma remains a considerable therapeutic challenge.
  • Endoscopic submucosal dissection (ESD) is a more recent approach that is now commonly used for radical resection of gastric adenoma and adenocarcinoma.
  • AIM AND METHODS: The expression of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), and interleukin-6 (IL-6) are related to the prognosis of gastric adenocarcinoma.
  • However, the expression of these factors in gastric adenoma/adenocarcinoma following ESD has not been clearly evaluated.
  • Here, we report on our study of the expression of VEGF, EGFR, and IL-6 by immunohistochemical staining in extracted tissue from adenoma or adenocarcinoma of the stomach by ESD and subsequent evaluation of the correlation of VEGF, EGFR, and IL-6 with other clinicopathological parameters.
  • The patient cohort consisted of 102 patients with adenoma or adenocarcinoma of the stomach.
  • RESULTS: Immunohistochemical staining for VEGF and IL-6 was significantly higher in both high grade dysplasia and adenocarcinoma than in low grade dysplasia (P < 0.05).
  • Histological differentiation of adenocarcinoma was related to IL-6 expression (P = 0.028).
  • CONCLUSION: The immunohistochemical expression of IL-6 and VEGF can be considered to be useful for clinical diagnosis and follow-up of adenoma or adenocarcinoma of the stomach.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Interleukin-6 / metabolism. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / pathology. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):206-15 [14710231.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):324-31 [14991403.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Nov;17(11):1165-9 [12453275.001]
  • [Cites] J Pathol. 2000 Jul;191(3):239-44 [10878544.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1123-32 [17363505.001]
  • [Cites] Cancer Res. 1990 Mar 15;50(6):1774-8 [2155059.001]
  • [Cites] J Biomed Sci. 2004 Jul-Aug;11(4):517-27 [15153787.001]
  • [Cites] Histol Histopathol. 2000 Apr;15(2):455-62 [10809364.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2340-6 [10357403.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1458-68 [17516110.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Nov;1(6):438-45 [15017643.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2445-59 [15753456.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2787-99 [12860957.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):234-41 [12679307.001]
  • [Cites] Dig Liver Dis. 2008 Jul;40(7):504-9 [18486572.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1823-9 [10430087.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Mod Pathol. 2004 May;17(5):579-87 [15073595.001]
  • [Cites] Am J Obstet Gynecol. 1991 Apr;164(4):1038-42; discussion 1042-3 [2014824.001]
  • [Cites] J Surg Oncol. 2006 Dec 1;94(7):624-30 [17111394.001]
  • [Cites] Oncology. 1995 May-Jun;52(3):182-8 [7715901.001]
  • [Cites] J Clin Invest. 1989 Dec;84(6):2008-11 [2592570.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):206-13 [9010092.001]
  • [Cites] Blood. 1989 Sep;74(4):1360-7 [2788466.001]
  • [Cites] Lancet. 1994 Dec 3;344(8936):1576-7 [7983975.001]
  • [Cites] J Urol. 1992 Dec;148(6):1778-81; discussion 1781-2 [1433606.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1470-8 [2478587.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):98-106 [9210714.001]
  • [Cites] Jpn J Cancer Res. 1994 Oct;85(10):1045-9 [7525523.001]
  • [Cites] J Surg Oncol. 2001 Oct;78(2):132-7 [11579392.001]
  • [Cites] Immunol Today. 1990 Dec;11(12):443-9 [2127356.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):861-5 [9815760.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1111-5 [10836997.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3547-50 [17094480.001]
  • [Cites] Am J Gastroenterol. 1996 Jul;91(7):1417-22 [8678006.001]
  • [Cites] J Urol. 1992 Sep;148(3):791-4 [1512827.001]
  • [Cites] Dig Liver Dis. 2008 Aug;40(8):641-9 [18424243.001]
  • [Cites] Science. 1988 Aug 5;241(4866):708-12 [3041594.001]
  • (PMID = 19757047.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


29. Riccardi E, Grieco V, Verganti S, Finazzi M: Immunohistochemical diagnosis of canine ovarian epithelial and granulosa cell tumors. J Vet Diagn Invest; 2007 Jul;19(4):431-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Formalin-fixed, paraffin-embedded tissue sections from 4 normal ovaries, 8 granulosa cell tumors, and 6 epithelial ovarian tumors (2 adenomas and 4 adenocarcinomas) sections were obtained and stained with hematoxylin and eosin and immunohistochemically for cytokeratin AE1/AE3, cytokeratin 7, vimentin, and inhibin-alpha.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Vet Diagn Invest. 2007 Sep;19(5):586. Greco, Valeria [corrected to Grieco, Valeria]
  • (PMID = 17609358.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-7; 57285-09-3 / Inhibins
  •  go-up   go-down


30. Woicke J, Durham SK, Mense MG: Lobucavir-induced proliferative changes in mice. Exp Toxicol Pathol; 2007 Nov;59(3-4):197-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Light microscopically, lobucavir-induced neoplastic lesions consisted of upper digestive tract squamous cell neoplasia in males and females; cervical, vaginal, and cutaneous squamous cell neoplasia in females; and Hardarian gland adenomas and adenocarcinomas in male mice.

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942294.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Carcinogens; 5Z93L87A1R / Guanine; 8U5PYQ1R2E / lobucavir
  •  go-up   go-down


31. Choi HJ, Yun SS, Kim HJ, Choi JH: Expression of p16 protein in gallbladder carcinoma and its precancerous conditions. Hepatogastroenterology; 2010 Jan-Feb;57(97):18-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Adenocarcinoma of the gallbladder is a highly malignant neoplasm. p16 is a tumor suppressor gene protein, which is a cyclin-dependent kinase inhibitor that regulates the G1-S phase of the cell cycle.
  • METHODOLOGY: Formalin-fixed, paraffin-embedded tissue sections from 20 cases of normal gallbladder, 20 cases of chronic cholecystitis, 20 cases of gallbladder adenoma, 20 cases of dysplasia, and 58 cases of adenocarcinoma were examined.
  • In gallbladder adenomas, expression of p16 was found in 20% (4/20).
  • In gallbladder adenocarcinomas, p16 expression was found in 27.6% (16/58).
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Cholecystitis / metabolism. Gallbladder Neoplasms / metabolism. Neoplasm Proteins / metabolism. Precancerous Conditions / metabolism

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422865.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Neoplasm Proteins; 0 / P16 protein, human
  •  go-up   go-down


32. Yoshizawa K, Jelezcova E, Brown AR, Foley JF, Nyska A, Cui X, Hofseth LJ, Maronpot RM, Wilson SH, Sepulveda AR, Sobol RW: Gastrointestinal hyperplasia with altered expression of DNA polymerase beta. PLoS One; 2009 Aug 05;4(8):e6493
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We observed elevated expression of Pol beta in stomach adenomas and thyroid follicular carcinomas, but reduced Pol beta expression in esophageal adenocarcinomas and squamous carcinomas.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2007 Jan;21(1):26-34 [17116746.001]
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1748-54 [17230526.001]
  • [Cites] DNA Repair (Amst). 2007 Jun 1;6(6):695-711 [17337257.001]
  • [Cites] Nucleic Acids Res. 2007;35(8):2596-608 [17426133.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1356-63 [17166880.001]
  • [Cites] Stem Cells. 2007 Dec;25(12):3085-92 [17823235.001]
  • [Cites] Mol Cell. 2008 Feb 29;29(4):413-5 [18313379.001]
  • [Cites] Mol Cell. 2008 Feb 29;29(4):477-87 [18313385.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jun 27;371(2):225-9 [18433721.001]
  • [Cites] Mol Pharmacol. 2008 Aug;74(2):505-16 [18477668.001]
  • [Cites] Chin Med Sci J. 2008 Jun;23(2):108-12 [18686630.001]
  • [Cites] Cancer Lett. 2008 Nov 28;271(2):272-80 [18662849.001]
  • [Cites] Biol Reprod. 2008 Nov;79(5):824-31 [18650495.001]
  • [Cites] Gene. 2009 Jan 1;428(1-2):20-4 [18976699.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):740-6 [19147782.001]
  • [Cites] Carcinogenesis. 2009 May;30(5):763-8 [19237606.001]
  • [Cites] Cancer Res. 2009 Jun 15;69(12):5177-85 [19491276.001]
  • [Cites] J Biol Chem. 2004 Oct 15;279(42):43952-60 [15297456.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9470-7 [15485914.001]
  • [Cites] Cell Cycle. 2004 Aug;3(8):998-1001 [15280658.001]
  • [Cites] J Natl Cancer Inst. 1969 Dec;43(6):1353-64 [5396221.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):1938-43 [1149018.001]
  • [Cites] Lab Anim Sci. 1983 Jun;33(3):273-86 [6876733.001]
  • [Cites] Cancer Lett. 1984 Nov;25(1):19-23 [6518449.001]
  • [Cites] J Comp Pathol. 1986 Jan;96(1):89-94 [3455952.001]
  • [Cites] Lab Anim. 1989 Oct;23(4):324-7 [2811271.001]
  • [Cites] Exp Pathol. 1990;38(2):129-34 [2344869.001]
  • [Cites] Cancer Res. 1992 Sep 1;52(17):4824-7 [1511447.001]
  • [Cites] Science. 1994 Jul 1;265(5168):103-6 [8016642.001]
  • [Cites] Lab Anim Sci. 1994 Oct;44(5):531-3 [7844967.001]
  • [Cites] Cancer Lett. 1995 May 8;91(2):177-83 [7767907.001]
  • [Cites] Nature. 1996 Jan 11;379(6561):183-6 [8538772.001]
  • [Cites] Lab Invest. 1996 Feb;74(2):513-8 [8780168.001]
  • [Cites] J Exp Zool. 1997 Feb 15;277(3):245-54 [9062998.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10324-9 [9294209.001]
  • [Cites] Vet Pathol. 1997 Nov;34(6):605-14 [9396142.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9997-10002 [9707589.001]
  • [Cites] Carcinogenesis. 1999 Jun;20(6):1049-54 [10357787.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1825-30 [10469630.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7673-7 [15520167.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8526-33 [15574758.001]
  • [Cites] Nucleic Acids Res. 2005;33(1):280-8 [15647510.001]
  • [Cites] J Invest Surg. 2004 Nov-Dec;17(6):327-31 [15764500.001]
  • [Cites] DNA Repair (Amst). 2005 May 2;4(5):583-93 [15811630.001]
  • [Cites] EMBO J. 2005 Jul 6;24(13):2447-57 [15933716.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6113-7 [10626800.001]
  • [Cites] EMBO J. 2000 Mar 15;19(6):1397-404 [10716939.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):807-10 [10866204.001]
  • [Cites] Leuk Res. 2000 Aug;24(8):705-18 [10936423.001]
  • [Cites] Carcinogenesis. 2000 Sep;21(9):1691-700 [10964101.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(1):298-309 [11113204.001]
  • [Cites] Science. 2001 Feb 16;291(5507):1284-9 [11181991.001]
  • [Cites] Langenbecks Arch Surg. 2001 Apr;386(3):163-71 [11382316.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6181-7 [11593426.001]
  • [Cites] J Mol Biol. 2002 Feb 1;315(5):1039-47 [11827474.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1524-30 [11888930.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6860-5 [11983862.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3511-4 [12067997.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6061-4 [12414629.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1213-22 [12453427.001]
  • [Cites] DNA Repair (Amst). 2002 Apr 29;1(4):317-33 [12509250.001]
  • [Cites] Curr Gastroenterol Rep. 2003 Apr;5(2):171-5 [12631460.001]
  • [Cites] DNA Repair (Amst). 2003 May 13;2(5):609-22 [12713817.001]
  • [Cites] Pathologe. 2003 May;24(3):196-203 [12739053.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5799-807 [14522902.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39951-9 [12882965.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1887-94 [14679184.001]
  • [Cites] FEBS Lett. 2004 May 21;566(1-3):147-50 [15147885.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3830-7 [15172990.001]
  • [Cites] Mol Cancer Ther. 2004 Aug;3(8):955-67 [15299078.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):223-31 [15368105.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6394-400 [16024643.001]
  • [Cites] Cell. 2005 Sep 23;122(6):957-68 [16169070.001]
  • [Cites] Mutagenesis. 2006 Jan;21(1):55-9 [16399847.001]
  • [Cites] Mol Cell. 2006 Apr 7;22(1):51-62 [16600869.001]
  • [Cites] Dis Esophagus. 2006;19(3):172-6 [16722994.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):523-5 [16739313.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7460-5 [16885342.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5104-11 [16951227.001]
  • [Cites] Cell. 2006 Nov 17;127(4):709-20 [17110331.001]
  • (PMID = 19654874.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / 1 R01 AG24364-01; United States / NIEHS NIH HHS / ES / Z01 ES050158; United States / NIEHS NIH HHS / ES / Z01 ES050159; United States / NIA NIH HHS / AG / R01 AG024364; United States / NCI NIH HHS / CA / 1P50 CA 097190 01A1; United States / NCI NIH HHS / CA / 1 P20 CA132385-01; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / P20 CA132385; United States / NCI NIH HHS / CA / P50 CA097190; United States / NCI NIH HHS / CA / P20 CA103730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.- / DNA Polymerase beta
  • [Other-IDs] NLM/ PMC2716528
  •  go-up   go-down


33. Grahn BH, Peiffer RL, Cullen CL, Haines DM: Classification of feline intraocular neoplasms based on morphology, histochemical staining, and immunohistochemical labeling. Vet Ophthalmol; 2006 Nov-Dec;9(6):395-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Morphologic diagnoses included 33 intraocular sarcomas, 17 diffuse iris melanomas, 15 lymphosarcomas, three ciliary adenomas, one metastatic carcinoma, and six undifferentiated intraocular neoplasms.
  • These included four neoplasms morphologically diagnosed as lymphosarcomas but which expressed differentiation antigens consistent with melanoma (n = 3) or ciliary adenocarcinoma (n = 1), and four tumors morphologically diagnosed as intraocular sarcomas that expressed differentiation antigens for melanoma (n = 2), metastatic carcinoma (n = 1), or remained undifferentiated (n = 1).
  • Immunohistochemical labeling suggested a diagnosis in 5/6 morphologically undifferentiated neoplasms including one intraocular sarcoma, two diffuse iridal melanomas, and two ciliary adenocarcinomas.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / veterinary. Animals. Biomarkers, Tumor. Cats. Immunohistochemistry / veterinary. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / veterinary. Melanoma / diagnosis. Melanoma / veterinary. Sarcoma / diagnosis. Sarcoma / veterinary

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076872.001).
  • [ISSN] 1463-5216
  • [Journal-full-title] Veterinary ophthalmology
  • [ISO-abbreviation] Vet Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


34. Kim HC, Roh SA, Ga IH, Kim JS, Yu CS, Kim JC: CpG island methylation as an early event during adenoma progression in carcinogenesis of sporadic colorectal cancer. J Gastroenterol Hepatol; 2005 Dec;20(12):1920-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CpG island methylation as an early event during adenoma progression in carcinogenesis of sporadic colorectal cancer.
  • We evaluated the methylation status of primary colorectal tumors to determine its role in the adenoma to carcinoma sequence.
  • METHODS: The methylation status of APC, THBS1, MGMT, hMLH1 and GSTP1, as determined by methylation specific PCR (MSP), and microsatellite instability (MSI) using three mononucleotide markers were assessed in 40 colorectal adenomas and 36 adenocarcinomas.
  • RESULTS: Of the 40 adenomas, 24 (60%) were methylated at one or more loci, and 12 (30%) at two or more loci (CpG island methylation phenotype-high, CIMP-H).
  • THBSI was the most frequently methylated locus in both adenomas (n = 19, 47.5%) and carcinomas (n = 16, 44.4%).
  • Overall, methylation status of adenomas and carcinomas did not differ significantly (P = 0.53), nor did the methylation status of individual genes.
  • For adenomas, size (P = 0.049) and histologic classification of the villous components (P = 0.018) were each associated with methylation status.
  • MSI was detected in three adenomas (7.5%) and five carcinomas (13.9%), and was closely correlated with hMLH1 methylation (P < 0.001).
  • CONCLUSIONS: In colorectal tumors, CpG island methylation of tumor suppressor genes appears to be common and may be involved in the progression of adenomas.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Cell Transformation, Neoplastic / genetics. Colorectal Neoplasms / genetics. CpG Islands / genetics. DNA Methylation

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Blackwell Publishing Asia Pty Ltd.
  • [ErratumIn] J Gastroenterol Hepatol. 2005 Dec;20(12):1951
  • (PMID = 16336454.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


35. Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z: Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer; 2009;9:40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Immunohistochemistry detected significant PADI4 expression in various malignancies including breast carcinomas, lung adenocarcinomas, hepatocellular carcinomas, esophageal squamous cancer cells, colorectal adenocarcinomas, renal cancer cells, ovarian adenocarcinomas, endometrial carcinomas, uterine adenocarcinomas, bladder carcinomas, chondromas, as well as other metastatic carcinomas.
  • However, PADI4 expression was not observed in benign leiomyomas of stomach, uterine myomas, endometrial hyperplasias, cervical polyps, teratomas, hydatidiform moles, trophoblastic cell hyperplasias, hyroid adenomas, hemangiomas, lymph hyperplasias, schwannomas, neurofibromas, lipomas, and cavernous hemangiomas of the liver.
  • Quantitative PCR and western blot analysis showed higher PADI4 expression in gastric adenocarcinomas, lung adenocarcinomas, hepatocellular carcinomas, esophageal squamous cell cancers and breast cancers (n = 5 for each disease) than in the surrounding healthy tissues.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 1998 May-Jun;84(3):364-7 [9678618.001]
  • [Cites] Pathologe. 1996 Nov;17(6):425-32 [9082363.001]
  • [Cites] J Cell Mol Med. 2004 Oct-Dec;8(4):498-508 [15601578.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(4):235-40 [15704650.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):293-8 [15561738.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):309-18 [15907383.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2936-42 [16365013.001]
  • [Cites] Mol Carcinog. 2006 Mar;45(3):183-96 [16355400.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Mol Endocrinol. 2007 Jul;21(7):1617-29 [17456793.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):76-80 [17826626.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1682-9 [18350599.001]
  • [Cites] Histochem Cell Biol. 2008 Jun;129(6):705-33 [18461349.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):475-83 [18509000.001]
  • [Cites] J Biol Chem. 2008 Jul 18;283(29):20060-8 [18499678.001]
  • [Cites] Mol Cell Biol. 2008 Aug;28(15):4745-58 [18505818.001]
  • [Cites] Adv Exp Med Biol. 2008;630:112-32 [18637488.001]
  • [Cites] Histopathology. 2001 Jan;38(1):62-7 [11135048.001]
  • [Cites] Cell Death Differ. 2002 May;9(5):486-92 [11973607.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):173-7 [12023846.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):201-7 [12023851.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):395-402 [12833157.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2004 Sep;18(3):385-405 [15212335.001]
  • [Cites] Cell. 2004 Sep 3;118(5):545-53 [15339660.001]
  • [Cites] Anticancer Res. 1990 May-Jun;10(3):579-82 [2114816.001]
  • [Cites] APMIS. 1991 Nov;99(11):981-8 [1720319.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(3):209-15 [1384221.001]
  • [Cites] Int J Cancer. 1993 Jul 9;54(5):793-806 [7686887.001]
  • [Cites] Thromb Haemost. 1998 Nov;80(5):767-72 [9843169.001]
  • (PMID = 19183436.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antithrombins; 0 / Neoplasm Proteins; 29VT07BGDA / Citrulline; EC 3.- / Hydrolases; EC 3.5.3.15 / peptidylarginine deiminase type IV
  • [Other-IDs] NLM/ PMC2637889
  •  go-up   go-down


36. Perse M, Zebic A, Cerar A: Rofecoxib does not inhibit aberrant crypt foci formation but inhibits later steps in the development of experimental colorectal cancer: rofecoxib in experimental colon cancer. Scand J Gastroenterol; 2005 Jan;40(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal tumours were evaluated quantitatively and histopathologically for the presence of aberrant crypt foci (ACF), adenomas and adenocarcinomas.
  • However, a significant lower incidence of adenomas (p < 0.05), adenocarcinomas (p < 0.05) and decreased volume of macroscopically visible tumours (by 42%) was found in the experimental group.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841716.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Lactones; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib
  •  go-up   go-down


37. Redente EF, Orlicky DJ, Bouchard RJ, Malkinson AM: Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am J Pathol; 2007 Feb;170(2):693-708
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neutrophils infiltrated the alveoli of tumor-bearing lungs and within the periphery of macroscopic adenomas and adenocarcinomas.
  • These biochemical markers of macrophage activation states would have diagnostic and/or therapeutic value if analogous systemic shifts occur in humans.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2001 Jun;32(3):265-79 [11390008.001]
  • [Cites] J Histochem Cytochem. 2001 Aug;49(8):1061-2 [11457936.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cell. 2006 Feb 10;124(3):615-29 [16469706.001]
  • [Cites] J Immunol. 2006 Apr 15;176(8):5023-32 [16585599.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1423-33 [11583970.001]
  • [Cites] Toxicology. 2001 Dec 1;169(1):1-15 [11696405.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6178-84 [10626810.001]
  • [Cites] Cell Prolif. 1999 Dec;32(6):351-61 [10646687.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):509-18 [10666380.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Feb 15;165(4):508-13 [11850344.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6850-6 [12460898.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Nat Rev Immunol. 2003 Jan;3(1):23-35 [12511873.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):186-98 [12539173.001]
  • [Cites] Clin Lung Cancer. 2003 Jul;5(1):46-62 [14596704.001]
  • [Cites] Cell Mol Life Sci. 2003 Nov;60(11):2334-46 [14625680.001]
  • [Cites] Novartis Found Symp. 2004;256:137-45; discussion 146-8, 259-69 [15027487.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3458-64 [15150098.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2053-8 [15164120.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(11):1660-7 [15251154.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5084-8 [15289309.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7022-9 [15466195.001]
  • [Cites] J Cell Sci. 1966 Sep;1(3):297-310 [4291022.001]
  • [Cites] Int J Cancer. 1967 Jul 15;2(4):326-36 [6055972.001]
  • [Cites] Cancer Res. 1969 May;29(5):994-8 [5781107.001]
  • [Cites] J Natl Cancer Inst. 1983 May;70(5):931-6 [6573537.001]
  • [Cites] Immunology. 1984 Dec;53(4):753-67 [6389324.001]
  • [Cites] J Natl Cancer Inst. 1985 Nov;75(5):963-9 [3863993.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5335-8 [3756882.001]
  • [Cites] Am J Surg Pathol. 1988 Dec;12(12):918-31 [2849325.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(9):3070-4 [2654935.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Immunol. 1992 Oct 15;149(8):2709-14 [1401910.001]
  • [Cites] N Engl J Med. 1993 Jan 28;328(4):257-65 [8418407.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4848-50 [8069850.001]
  • [Cites] J Exp Med. 1994 Oct 1;180(4):1415-25 [7931074.001]
  • [Cites] Genet Res. 1994 Oct;64(2):99-106 [7813906.001]
  • [Cites] Dis Colon Rectum. 1995 Mar;38(3):290-3 [7882795.001]
  • [Cites] Int J Cancer. 1997 Jul 29;72(3):385-8 [9247277.001]
  • [Cites] Am J Physiol. 1998 Nov;275(5 Pt 1):E740-7 [9814991.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Trends Immunol. 2004 Dec;25(12):677-86 [15530839.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Exp Lung Res. 2005 Jan-Feb;31(1):57-82 [15765919.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3226-35 [15833854.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):752-3 [15944689.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10280-8 [16288016.001]
  • [Cites] FASEB J. 2005 Dec;19(14):2005-7 [16223785.001]
  • [Cites] J Submicrosc Cytol Pathol. 2005 Aug;37(2):109-204 [16335592.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4198-207 [16618742.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):846-55 [16788158.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):197-202 [16337739.001]
  • [Cites] Lung Cancer. 2000 Jan;27(1):27-35 [10672781.001]
  • [Cites] J Immunol. 2000 Jun 15;164(12):6166-73 [10843666.001]
  • [Cites] Eur Respir J. 2000 Jun;15(6):1087-93 [10885428.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Dec;279(6):R2237-42 [11080091.001]
  • [Cites] Curr Opin Immunol. 2000 Dec;12(6):624-31 [11102764.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Jan;280(1):E75-82 [11120661.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • (PMID = 17255336.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA033497; United States / NCI NIH HHS / CA / R01 CA096133; United States / NCI NIH HHS / CA / CA33497; United States / NCI NIH HHS / CA / CA96133
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinogens; 3IN71E75Z5 / Urethane; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nos2 protein, mouse
  • [Other-IDs] NLM/ PMC1851863
  •  go-up   go-down


38. Bucher P, Chassot G, Durmishi Y, Ris F, Morel P: Long-term results of surgical treatment of Vater's ampulla neoplasms. Hepatogastroenterology; 2007 Jun;54(76):1239-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among the ampullary neoplasms, 10 were adenomas (median age 71) and 45 adenocarcinomas (median age 69).
  • Of the adenomas 60% were treated surgically with excellent long-term results.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629078.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


39. Kim JY, Park DY, Kim GH, Choi KU, Lee CH, Huh GY, Sol MY, Song GA, Jeon TY, Kim DH, Sim MS: Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma. Histol Histopathol; 2005 04;20(2):543-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma.
  • The purpose of this study was to elucidate Smad4 expression and localization in 65 gastric adenomas, 49 intestinal-type and 39 diffuse type of gastric adenocarcinomas (including 12 cases of fresh frozen tissue) using Real-time RT-PCR and immunohistochemistry.
  • Real-time RT-PCR showed that intestinal type gastric adenocarcinomas have higher Smad4 mRNA expression than diffuse type gastric adenocarcinomas.
  • Immunohistochemical stain for Smad4 revealed that expression of Smad4 was significantly lower in diffuse-type gastric adenocarcinoma than intestinal-type gastric adenocarcinomas.
  • Also, higher Smad4 protein expression in intestinal type gastric adenocarcinomas than overall gastric adenoma was noted.
  • These results suggest that Smad4 might play different roles in human gastric carcinogenesis, especially between intestinal type and diffuse type of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. Trans-Activators / genetics. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15736060.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Trans-Activators; 0 / Transforming Growth Factor beta
  •  go-up   go-down


40. Ozaki M, Ozaki K, Watanabe T, Uwagawa S, Okuno Y, Shirai T: Susceptibilities of p53 knockout and rasH2 transgenic mice to urethane-induced lung carcinogenesis are inherited from their original strains. Toxicol Pathol; 2005;33(2):267-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At week 26, lung adenocarcinomas and adenomas were observed in 53% and 100% of rasH2 mice, respectively, and lung adenomas were observed in 67% of rasH2 littermate (non-Tg) mice.
  • Under the same experimental conditions, BALB/c mice, the strain of origin of the rasH2 mice, developed lung adenomas at an incidence of 93%, whereas none of the C57BL/6 original strain for p53 (+/-) mice developed lung tumors.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Genes, p53. Genes, ras. Genetic Predisposition to Disease. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902970.001).
  • [ISSN] 0192-6233
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 3IN71E75Z5 / Urethane
  •  go-up   go-down


41. Newman RJ, Nichols DB, Cummings DM: Outpatient colonoscopy by rural family physicians. Ann Fam Med; 2005 Mar-Apr;3(2):122-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The adenoma detection rate was 27.2% for men and 21.4% for women older than age 50 years.
  • Six adenocarcinomas and 5 large (>2 cm) villous adenomas were detected, and the patients were referred for definitive surgical resection.

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] J Fam Pract. 1996 Dec;43(6):561-6 [8969704.001]
  • [Cites] J Fam Pract. 1997 May;44(5):473-80 [9152265.001]
  • [Cites] Fam Med. 1997 Sep;29(8):575-9 [9310757.001]
  • [Cites] Tenn Med. 1998 Jan;91(1):21-6 [9439182.001]
  • [Cites] J Am Board Fam Pract. 1998 Nov-Dec;11(6):492-6 [9876008.001]
  • [Cites] Gastrointest Endosc. 2001 Nov;54(5):662-7 [11677497.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1296-308 [12094842.001]
  • [Cites] Rev Gastroenterol Disord. 2001;1(2):73-86 [12120177.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):352-7 [12612515.001]
  • [Cites] JAMA. 2003 Mar 12;289(10):1288-96 [12633191.001]
  • [Cites] JAMA. 2003 Mar 12;289(10):1297-302 [12633192.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] Fam Med. 2004 Jun;36(6):407-11 [15181552.001]
  • [Cites] Fam Pract Res J. 1992 Sep;12(3):313-20 [1414436.001]
  • [Cites] Fam Pract Res J. 1993 Mar;13(1):43-52 [8484340.001]
  • [Cites] Arch Fam Med. 1997 Jan-Feb;6(1):52-8 [9003171.001]
  • (PMID = 15798037.001).
  • [ISSN] 1544-1717
  • [Journal-full-title] Annals of family medicine
  • [ISO-abbreviation] Ann Fam Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1466847
  •  go-up   go-down


42. Hare HH, Mahendraker N, Sarwate S, Tangella K: Muir-Torre syndrome: a rare but important disorder. Cutis; 2008 Oct;82(4):252-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sebaceous adenomas, sebaceous carcinomas, and sebaceomas (sebaceous epitheliomas) are all characteristic glandular tumors of MTS.
  • We report 2 patients with MTS who developed colon adenocarcinomas in conjunction with sebaceous carcinomas.

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055168.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Li J, Guo K, Koh VW, Tang JP, Gan BQ, Shi H, Li HX, Zeng Q: Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases. Clin Cancer Res; 2005 Mar 15;11(6):2195-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most importantly, the PRL-3 mAbs were assessed on 282 human colorectal tissue samples (121 normal, 17 adenomas, and 144 adenocarcinomas).
  • PRL-3 protein was detected in 11% of adenocarcinoma samples.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Antibodies, Monoclonal. Biomarkers, Tumor / immunology. Colorectal Neoplasms / diagnosis. Immediate-Early Proteins / immunology. Protein Tyrosine Phosphatases / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788667.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Immediate-Early Proteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; EC 3.1.3.48 / PTP4A1 protein, human; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


44. Serra Aracil X, Bombardó Juncá J, Mora López L, Alcantara Moral M, Ayguavives Garnica I, Darnell Marti A, Casalots Casado A, Pericay Pijaume C, Campo Fernández de Los Ríos R, Navarro Soto S: [Site of local surgery in adenocarcinoma of the rectum T2N0M0]. Cir Esp; 2009 Feb;85(2):103-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Site of local surgery in adenocarcinoma of the rectum T2N0M0].
  • [Transliterated title] Lugar de la cirugía local en el adenocarcinoma de recto T(2)N(0)M(0).
  • INTRODUCTION: The local exeresis adenocarcinoma of the rectum T(2)N(0)M(0) (ADC-T2), using transanal endoscopic microsurgery (TEM), has the benefit of achieving lower morbidity with a better quality of life.
  • RESULTS: Of the 146 patients operated on using TEM, 75 had adenocarcinomas, 59 adenomas, 6 scarring wounds, 5 carcinoids and 1 GIST.
  • Of the adenocarcinomas 22 were ADC-T2.
  • [MeSH-major] Adenocarcinoma / surgery. Rectal Neoplasms / surgery

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231466.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


45. Götte K, Ganssmann S, Affolter A, Schäfer C, Riedel F, Arens N, Finger S, Hörmann K: Dual FISH analysis of benign and malignant tumors of the salivary glands and paranasal sinuses. Oncol Rep; 2005 Nov;14(5):1103-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined 58 of these tumors (14 adenoid cystic carcinomas, 9 adenocarcinomas, 5 cylindrical carcinomas, 11 pleomorphic adenomas, and 19 inverted papillomas) by dual fluorescence in situ hybridization (FISH) with centromere-specific probes on six chromosomes (3, 7, 9, 11, 17, and 18) for numerical changes.
  • In adenocarcinomas, monosomy of chromosome 17 and polysomy of chromosomes 7 and 11 were most frequent.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenoma / diagnosis. Adenoma / genetics. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / genetics. Chromosome Aberrations. Papilloma / diagnosis. Papilloma / genetics. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211271.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


46. Su MY, Hsu CM, Lin CJ, Ho YP, Chiu CT, Chen PC, Lien JM, Wu CS, Tung SY: Endoscopic treatment of colorectal neoplasms: a simple and safe procedure to lower the incidence of colorectal cancers. Dig Dis Sci; 2008 May;53(5):1297-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Histological diagnoses were 8,333 neoplastic lesions (8,246 adenomas with low/high-grade dysplasia and 87 invasive adenocarcinomas) and 1,201 non-neoplastic lesions (1,186 hyperplastic and 15 inflammatory polyps).
  • For the adenocarcinoma group, all had received further operations, while 73 surgical specimens discovered no residual tumors.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1998 Nov;43(5):669-74 [9824349.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):224-7 [10064750.001]
  • [Cites] Ann R Coll Surg Engl. 1976 May;58(3):241-2 [1267378.001]
  • [Cites] Dis Colon Rectum. 1982 Oct;25(7):669-72 [7128368.001]
  • [Cites] Endoscopy. 1993 Sep;25(7):455-61 [8261988.001]
  • [Cites] Gastroenterologist. 1993 Jun;1(2):158-64 [8049888.001]
  • [Cites] Dis Colon Rectum. 1992 Feb;35(2):178-81 [1735321.001]
  • [Cites] Cancer. 1963 Jun;16:751-64 [13928507.001]
  • [Cites] Hepatogastroenterology. 1997 Jan-Feb;44(13):108-15 [9058127.001]
  • [Cites] Surg Endosc. 1994 Jun;8(6):672-6 [8059305.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] Dis Colon Rectum. 1994 Nov;37(11):1108-11 [7956578.001]
  • [Cites] Am J Gastroenterol. 1993 Sep;88(9):1421-3 [8362841.001]
  • [Cites] J Clin Pathol. 1968 Nov;21(6):735-43 [5717544.001]
  • [Cites] World J Surg. 1997 Sep;21(7):694-701 [9276699.001]
  • [Cites] Gastrointest Endosc. 1993 Jul-Aug;39(4):592-3 [8365620.001]
  • [Cites] Dig Dis Sci. 2004 Aug;49(7-8):1123-7 [15387332.001]
  • [Cites] Dis Colon Rectum. 1987 Apr;30(4):247-50 [3829872.001]
  • [Cites] Am J Gastroenterol. 2001 Sep;96(9):2628-32 [11569686.001]
  • [Cites] Arch Intern Med. 1988 Feb;148(2):473-5 [3341844.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Cancer. 1974 Sep;34(3):suppl:845-9 [4851945.001]
  • [Cites] Gastroenterology. 1991 Feb;100(2):564-6 [1985054.001]
  • (PMID = 18363105.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Ikehara N, Semba S, Sakashita M, Aoyama N, Kasuga M, Yokozaki H: BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. Int J Cancer; 2005 Jul 20;115(6):943-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven colon cancer cell lines and 116 colorectal tumors (34 adenomas and 82 adenocarcinomas) were analyzed.
  • In tumor samples, BRAF mutations were found in 1 (3.0%) of 33 adenomas and 6 (7.2%) of 83 adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenoma / genetics. Base Sequence. Cell Proliferation. DNA Fragmentation. Enzyme Inhibitors / pharmacology. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Polymorphism, Single-Stranded Conformational. Tumor Cells, Cultured


48. Westernoff TH, Jordan RC, Regezi JA, Ramos DM, Schmidt BL: Beta-6 Integrin, tenascin-C, and MMP-1 expression in salivary gland neoplasms. Oral Oncol; 2005 Feb;41(2):170-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 55 formalin-fixed, paraffin-embedded archived specimens comprising 19 adenoid cystic carcinomas (ACC), 18 polymorphous low-grade adenocarcinomas (PLGA) and 18 pleomorphic adenomas (PA) were utilized in this study.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenoma / metabolism. Carcinoma, Adenoid Cystic / metabolism. Humans. Immunohistochemistry / methods

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15695119.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 11RT-0141; United States / PHS HHS / / 12KT-0166; United States / NCI NIH HHS / CA / CA095231; United States / NIDCR NIH HHS / DE / DE14609; United States / NIDCR NIH HHS / DE / K23DE00443; United States / NIDCR NIH HHS / DE / P01DE13904; United States / NIDCR NIH HHS / DE / R0I DE12856; United States / NIDCR NIH HHS / DE / R0I DEO11930
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Integrin beta Chains; 0 / Neoplasm Proteins; 0 / Tenascin; 0 / integrin beta6; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


49. Lee KS, Lee YS, Lee JM, Ito K, Cinghu S, Kim JH, Jang JW, Li YH, Goh YM, Chi XZ, Wee H, Lee HW, Hosoya A, Chung JH, Jang JJ, Kundu JK, Surh YJ, Kim WJ, Ito Y, Jung HS, Bae SC: Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer. Oncogene; 2010 Jun 10;29(23):3349-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human lung adenocarcinoma, the most prevalent form of lung cancer, is characterized by many molecular abnormalities.
  • K-ras mutations are associated with the initiation of lung adenocarcinomas, but K-ras-independent mechanisms may also initiate lung tumors.
  • Here, we find that the runt-related transcription factor Runx3 is essential for normal murine lung development and is a tumor suppressor that prevents lung adenocarcinoma.
  • Lung adenomas spontaneously develop in aging Runx3+/- mice ( approximately 18 months after birth) and invariably exhibit reduced levels of Runx3.
  • As K-ras mutations are very rare in these adenomas, Runx3+/- mice provide an animal model for lung tumorigenesis that recapitulates the preneoplastic stage of human lung adenocarcinoma development, which is independent of K-Ras mutation.
  • We conclude that Runx3 is essential for lung epithelial cell differentiation, and that downregulation of Runx3 is causally linked to the preneoplastic stage of lung adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Animals. Cell Differentiation. Cell Proliferation. Epithelial Cells / cytology. Humans. Mice. Mice, Inbred C57BL. Nuclear Proteins / analysis. Nuclear Proteins / physiology. Polycomb Repressive Complex 1. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins / physiology. Proto-Oncogene Proteins p21(ras) / genetics. Pulmonary Surfactant-Associated Protein B / analysis. Repressor Proteins / analysis. Repressor Proteins / physiology. Urethane / toxicity. Uteroglobin / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20228843.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bmi1 protein, mouse; 0 / Core Binding Factor Alpha 3 Subunit; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Pulmonary Surfactant-Associated Protein B; 0 / Repressor Proteins; 0 / Runx3 protein, human; 0 / Runx3 protein, mouse; 0 / SCGB1A1 protein, human; 0 / Scgb1a1 protein, mouse; 3IN71E75Z5 / Urethane; 9060-09-7 / Uteroglobin; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


50. Nemolato S, Ravarino A, Fanni D, Coni P, Di Felice E, Senes G, Faa G: Hepatocyte Paraffin 1 Immunoreactivity in Early Colon Carcinogenesis. Gastroenterology Res; 2009 Oct;2(5):277-281
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: To this end, 50 intestinal biopsies were analyzed including 10 colorectal polyps with low grade dysplasia, 10 with high grade dysplasia, 10 colorectal adenocarcinomas, 10 specimens of normal ileum and 10 of normal colon mucosa.
  • Hep par 1 was frequently detected in the deepest areas of adenocarcinomas mainly in infiltrating tumour cells.
  • CONCLUSIONS: Our data show that Hep par 1 immunoreactivity in human colon carcinogenesis is correlated with progression from low grade to high grade dysplasia and adenocarcinoma.
  • In clinical practice, our data show that caution should be taken in utilizing Hep par 1 as the sole tool in differentiating hepatocellular carcinoma from a liver metastasis of colon adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27956971.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Colorectal adenocarcinomas / Colorectal adenomas / Colorectal polyps / Hepatocyte paraffin 1
  •  go-up   go-down


51. Payne CM, Holubec H, Bernstein C, Bernstein H, Dvorak K, Green SB, Wilson M, Dall'Agnol M, Dvorakova B, Warneke J, Garewal H: Crypt-restricted loss and decreased protein expression of cytochrome C oxidase subunit I as potential hypothesis-driven biomarkers of colon cancer risk. Cancer Epidemiol Biomarkers Prev; 2005 Sep;14(9):2066-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These included five patients without evidence of colonic neoplasia (three normal and two diverticulitis), three patients with tubulovillous adenomas, and eight patients with colonic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Electron Transport Complex IV / genetics. Gene Expression Profiling

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172211.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA23074; United States / NCI NIH HHS / CA / CA72008; United States / NCI NIH HHS / CA / P50CA95060-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.9.3.1 / Electron Transport Complex IV
  •  go-up   go-down


52. Wen Y, Giardina SF, Hamming D, Greenman J, Zachariah E, Bacolod MD, Liu H, Shia J, Amenta PS, Barany F, Paty P, Gerald W, Notterman D: GROalpha is highly expressed in adenocarcinoma of the colon and down-regulates fibulin-1. Clin Cancer Res; 2006 Oct 15;12(20 Pt 1):5951-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GROalpha is highly expressed in adenocarcinoma of the colon and down-regulates fibulin-1.
  • Expression of GROalpha mRNA was higher in primary adenocarcinomas (n = 132), adenomas (n = 32), and metastases (n = 52) than in normal colon epithelium (P < 0.001).
  • CONCLUSION: Elevated expression of GROalpha is frequent in adenocarcinoma of the colon and is associated with down-regulation of the matrix protein fibulin-1 in experimental models and in clinical samples.
  • [MeSH-major] Adenocarcinoma / genetics. Calcium-Binding Proteins / genetics. Chemokines, CXC / genetics. Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Intercellular Signaling Peptides and Proteins / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062666.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA65930; United States / NCI NIH HHS / CA / P30-CA072720
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL1 protein, human; 0 / Calcium-Binding Proteins; 0 / Chemokine CXCL1; 0 / Chemokines, CXC; 0 / DNA, Neoplasm; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / fibulin
  •  go-up   go-down


53. Mosnier JF, Kandel C, Cazals-Hatem D, Bou-Hanna C, Gournay J, Jarry A, Laboisse CL: N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mod Pathol; 2009 Feb;22(2):182-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Normal liver tissue, 5 cirrhosis with ductular reaction, 5 focal nodular hyperplasia, 5 bile duct hamartomas, 5 bile duct adenomas, and 45 intrahepatic cholangiocarcinomas from Caucasian patients were studied.
  • Tissue-microarrays including 20 esophageal, 86 gastric, 8 small bowel, 64 colonic, 18 pancreatic, 6 gallbladder, and 7 extrahepatic biliary tract adenocarcinomas, 22 hepatocellular carcinomas, and normal tissues were constructed.
  • Among noncholangiocarcinomas, only 1% gastric and 66% gallbladder adenocarcinomas and all the hepatocellular carcinomas expressed N-cadherin at the membrane of tumor cells.
  • Finally, for the diagnosis of intrahepatic cholangiocarcinomas, the specificity value of membranous expression of N-cadherin was 88%, whereas that of the combination cytokeratin 7/membranous N-cadherin was 98%.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. France. Humans. Immunoblotting. Immunohistochemistry. Keratin-7 / analysis. Male. Middle Aged. Predictive Value of Tests. Reproducibility of Results. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622386.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDH1 protein, human; 0 / CDH2 protein, human; 0 / Cadherins; 0 / KRT7 protein, human; 0 / Keratin-7
  •  go-up   go-down


54. López-Köstner F, Fullerton DA, Kronberg U, Soto G, Zúñiga A, Argandoña J, Miranda V, Pinto E: [Screening colonoscopy among first degree relatives of patients with colorectal carcinoma]. Rev Med Chil; 2006 Aug;134(8):997-1001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the latter, a neoplasm was found in 13 (17%): One adenocarcinoma and 12 adenomas.
  • CONCLUSIONS: Screening colonoscopy is effective to detect adenoma and adenocarcinoma among first degree relatives of patients with colorectal carcinoma, however only 31% of all potential relatives agreed to undergo a colonoscopy.
  • [MeSH-major] Adenoma / diagnosis. Colonoscopy / standards. Colorectal Neoplasms / diagnosis. Family Health. Mass Screening / psychology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adult. Age Factors. Aged. Attitude. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Pedigree. Prospective Studies. Risk Assessment


55. Olschwang S, Blanché H, de Moncuit C, Thomas G: Similar colorectal cancer risk in patients with monoallelic and biallelic mutations in the MYH gene identified in a population with adenomatous polyposis. Genet Test; 2007;11(3):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A large proportion of non-FAP non-HNPCC patients with multiple colorectal adenomas have been reported to carry germline mutations on the MYH gene.
  • Although the number of adenomas appears to be dependent on the number of mutated MYH alleles present in a patient, little is known on the relation of this number with cancer risk.
  • Four hundred fifty-three APC-negative patients with more than five colorectal adenomas were screened for mutations on the entire coding sequence of the MYH gene.
  • However, mutation copy number was correlated neither with the age at diagnosis of adenomas or adenocarcinomas, nor with the presence of a family history of colorectal tumors.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17949294.001).
  • [ISSN] 1090-6576
  • [Journal-full-title] Genetic testing
  • [ISO-abbreviation] Genet. Test.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase
  •  go-up   go-down


56. Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB, Dursun A: Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol; 2005 Sep;27(3):225-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
  • METHODS: Sections of adenoma, intramucosal carcinoma and adenocarcinoma were evaluated by immunohistochemistry in 85 malignant and 37 benign colorectal neoplasms for the expression of VEGF, c-erbB-2 and c-erbB-3 considering clinicopathological variables.
  • RESULTS: VEGF was detected in comparable percentages of all neoplasm types while c-erbB-2 expression was detectable more frequently in adenoma than adenocarcinoma cases (65% vs 43%).
  • Except for the correlation of c-erbB-3 expression with Dukes' staging, there was no correlation between the studied markers and grade of differentiation, Dukes' stage and localization of colorectal adenocarcinoma. c-erbB-3 expression was seen more frequently in tubular adenomas, while c-erbB-2 expression was higher in tubulovillous and villous types.
  • CONCLUSION: These results suggest that VEGF, c-erbB-2, c-erbB-3 expression does not have prognostic value in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colorectal Neoplasms / genetics. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-3 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244586.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


57. Szanto I, Rubbia-Brandt L, Kiss P, Steger K, Banfi B, Kovari E, Herrmann F, Hadengue A, Krause KH: Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol; 2005 Oct;207(2):164-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, there was no statistical difference in NOX1 expression between samples derived from adenomas, well differentiated or poorly differentiated colon adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Animals. Colitis, Ulcerative / metabolism. Colon / metabolism. Crohn Disease / metabolism. Female. Humans. Ileum / metabolism. In Situ Hybridization / methods. Lymphocytes / metabolism. Male. Mice. Mice, Inbred BALB C. Middle Aged. Neoplasm Proteins / analysis. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Rectal Neoplasms / metabolism. Rectum / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16086438.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Reactive Oxygen Species; EC 1.6.3.- / NOX1 protein, human; EC 1.6.3.1 / NADPH Oxidase
  •  go-up   go-down


58. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


59. National Toxicology Program: Toxicology and carcinogenesis studies of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study). Natl Toxicol Program Tech Rep Ser; 2008 Jan;(545):1-240
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In F(1)C females, there was a significant positive trend in the incidences of mammary gland adenoma or adenocarcinoma (combined) regardless of whether an unmodified or natural log-transformed dose scale was used in the analysis, and the incidence in the 500 ppm group was significantly greater than that in the control group.
  • In 5 and 100 ppm F(1)T140 females, the combined incidences of adenoma and adenocarcinoma were less than those in the control or 500 ppm groups, although these were not statistically significant differences.
  • When the natural log-transformed dose scale was used, a marginally significant positive trend occurred in the incidences of adenoma or adenocarcinoma (combined) in F(3)T21 females.
  • There were positive trends in the incidences of adenoma or carcinoma (combined) in the pars distalis of the pituitary gland of females in the F(1)C and F(1)T140 arms, and the incidence in the 500 ppm group was significantly greater than that in the controls in the F(1)C study arm.
  • In F(1)C males, a significant positive trend (unmodified dose scale only) occurred in the incidences of combined adenoma or carcinoma of the pancreatic islets.
  • There was some evidence of carcinogenic activity of genistein in female Sprague-Dawley rats based on increased incidences of mammary gland adenoma or adenocarcinoma (combined) and pituitary gland neoplasms.
  • There was equivocal evidence of carcinogenic activity of genistein in female Sprague-Dawley rats based on increased incidences of mammary gland adenoma or adenocarcinoma (combined).

  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685716.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phytoestrogens; 0 / Xenobiotics; DH2M523P0H / Genistein
  •  go-up   go-down


60. Sun K, Huan Y, Unger PD: Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S. Arch Pathol Lab Med; 2008 Sep;132(9):1417-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
  • Adequate characterization of this tumor has been hampered by its rarity. alpha-Methylacyl-CoA racemase (AMACR)/P504S has been reported to be positive in prostatic adenocarcinoma, papillary renal cell carcinoma, and gastrointestinal neoplasmas; however, it has never been studied in clear cell carcinoma of the lower urinary tract.
  • DESIGN: Four cases of clear cell adenocarcinoma were retrieved from our archives: 2 cases from the urinary bladder (one each from a man and a woman) and 2 cases from the urethra (both from women, 1 in a diverticulum).
  • Because similar expression of P504S is also seen in nephrogenic adenomas, this marker should not be used to differentiate nephrogenic adenomas from clear cell adenocarcinomas.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / analysis. Racemases and Epimerases / biosynthesis. Urethral Neoplasms / metabolism. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788852.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CKAP4 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Membrane Proteins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


61. Ouaïssi M, Sielezneff I, Alves A, Pirro N, Heyries L, Robitail S, Consentino B, Payan MJ, Valleur P, Panis Y, Sastre B: [Long term outcome following 26 surgical ampullectomies]. Ann Chir; 2006 May;131(5):322-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Final pathological examination revealed 15 adenomas, 4 in situ adenocarcinomas, 2 endocrine tumors, and 5 other benign lesions.
  • [MeSH-minor] Adenocarcinoma / surgery. Adenoma / surgery. Adenomatous Polyposis Coli / surgery. Adult. Aged. Carcinoma in Situ / surgery. Cause of Death. Common Bile Duct Diseases / surgery. Female. Follow-Up Studies. Granuloma, Plasma Cell / surgery. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Somatostatinoma / surgery. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615931.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


62. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of the study was to investigate immunohistochemical markers of proliferation and apoptosis in colorectal adenomas and adenocarcinomas at the patients with cholecystectomy.
  • Fifty patients (40 with retained function of gallbladder and 10 patients with cholecystectomy) histologically diagnosed as proximal colon adenoma or adenocarcinoma were included into the study.
  • Colonoscopic biopsies have been taken from the lesion in cancer patients, and colonoscopic polypectomy has been performed for adenomas.
  • No significant difference was detected in the comparison of Ki-67 expression levels between the healthy mucosa and adenomas at the patients with cholecystectomy 43,4 +/- 3,45 (p > 0,05), but more prominent increase was revealed in adenocarcinomas 64,33 +/- 7,67% (p < 0,01).
  • At the patients without cholecystectomy the frequency of revealing p53 in adenomas does not vary, compared with healthy mucosa, however in adenocarcinomas p53 was not revealed at none case.
  • As a contrast, in group of the patients with cholecystectomy the frequency of revealing p53 in adenomas is considerably increased (up to 80%), and even in adenocarcinomas, p53 was revealed in 30,8% of cases.
  • At the patients with a cholecystectomy, the increase of proliferative activity is accompanied by increased apoptosis in adenomas and maintained apoptosis in adenocarcinomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


63. Baatrup G, Elbrønd H, Hesselfeldt P, Wille-Jørgensen P, Møller P, Breum B, Qvist N: Rectal adenocarcinoma and transanal endoscopic microsurgery. Diagnostic challenges, indications and short term results in 142 consecutive patients. Int J Colorectal Dis; 2007 Nov;22(11):1347-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal adenocarcinoma and transanal endoscopic microsurgery. Diagnostic challenges, indications and short term results in 142 consecutive patients.
  • PURPOSE: The objective of this study was to present short-term results of transanal endoscopic microsurgery (TEM) of rectal adenocarcinomas registered in a national database.
  • Multiple biopsies may be beneficial in the case of larger adenomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / diagnosis. Rectal Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol Suppl. 2003;(239):34-9 [14743881.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Eur J Surg Oncol. 1986 Dec;12(4):373-7 [3780991.001]
  • [Cites] Gut. 1984 May;25(5):437-44 [6714785.001]
  • [Cites] Dig Surg. 2005;22(3):182-9; discussion 189-90 [16137996.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):974-80 [12905551.001]
  • [Cites] Colorectal Dis. 2004 May;6(3):153-7 [15109377.001]
  • [Cites] Abdom Imaging. 2003 Nov-Dec;28(6):784-93 [14753591.001]
  • [Cites] BMJ. 2003 Nov 22;327(7425):1196-201 [14630754.001]
  • [Cites] Colorectal Dis. 2002 Nov;4(6):467-72 [12790922.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):200-6 [11852333.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1380-8 [15906120.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Dec;19(6):993-1005 [16338654.001]
  • [Cites] Colorectal Dis. 2000 Sep;2(5):252-63 [23578114.001]
  • (PMID = 17643251.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


64. Tachezy R, Jirasek T, Salakova M, Ludvikova V, Kubecova M, Horak L, Mandys V, Hamsikova E: Human papillomavirus infection and tumours of the anal canal: correlation of histology, PCR detection in paraffin sections and serology. APMIS; 2007 Mar;115(3):195-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In our recent study the presence of HPV was detected by PCR in biopsy specimens of 42 different anal tumours, including SCCA and its histological variants (n=22), adenocarcinomas (n=5), tubulovillous adenomas (n=5) and anal condylomas (n=10).
  • HPV16 was identified in one adenocarcinoma, while four cases were HPV negative.
  • Two adenomas showed presence of HPV16; one showed simultaneous positivity for HPV33.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HPV.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367464.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 9004-22-2 / Globins
  •  go-up   go-down


65. Amosenko FA, Korchagina EL, Matveeva TI, Vaganov IuE, Vlasov SB, Poltavets NV, Veselov VV, Gar'kavtseva RF, Poliakov AV: [Mutation analysis of K-ras protooncogene in colorectal adenocarcinomas and polyps in Russian patients]. Genetika; 2010 May;46(5):700-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mutation analysis of K-ras protooncogene in colorectal adenocarcinomas and polyps in Russian patients].
  • To estimate diagnostic value of K-ras mutations during cancer risk group formation, they were studied in the samples of sporadic carcinomas (n = 33) and malignant (n = 13) polyps of large intestine obtained during surgery or polypectomy.
  • The maximum mutation frequency was revealed in polyps of patients over 70 years of age as well as in the adenomas of villous histology and large size ((1 cm).
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA, Neoplasm / genetics. Genes, ras / genetics. Mutation

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583607.001).
  • [ISSN] 0016-6758
  • [Journal-full-title] Genetika
  • [ISO-abbreviation] Genetika
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm
  •  go-up   go-down


66. Kiziltaş S, Sezgin Ramadan S, Topuzoğlu A, Küllü S: Does the severity of tissue eosinophilia of colonic neoplasms reflect their malignancy potential? Turk J Gastroenterol; 2008 Dec;19(4):239-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This retrospective study aimed to investigate the frequency and intensity of tissue eosinophilia in various colonic neoplasms, including serrated adenomas.
  • METHODS: We evaluated 448 colonic neoplasms to determine eosinophilic infiltration: 96 hyperplastic polyps, 50 serrated adenomas, 19 flat adenomas, 154 tubular adenomas, 71 tubulovillous adenomas, 13 villous adenomas and 45 adenocarcinomas.
  • P value <0.05 was considered statistically significant.
  • RESULTS: Moderate (46.7%) and marked (52.9%) intensity were noted in all colonic adenomas.
  • Most of the hyperplastic polyps (96%) and adenocarcinomas (75.6%) showed mild intensity.
  • Mostly moderate eosinophilic infiltration was observed in serrated adenomas.
  • CONCLUSIONS: Our findings suggest that the intensity of tissue eosinophilia is most prominent in adenomas including serrated adenomas and is diminished from adenoma to carcinoma.

  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19119482.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


67. Ichihara T, Yoshino H, Doi Y, Nabae K, Imai N, Hagiwara A, Tamano S, Morita O, Tamaki Y, Suzuki H: No enhancing effects of diacylglycerol oil on tumor development in a medium-term multi-organ carcinogenesis bioassay using male F344 rats. Food Chem Toxicol; 2008 Jan;46(1):157-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of colon adenomas was significantly increased in rats given 1.375% DAG oil, but not 2.75% and 5.5% DAG oil, when compared to the control (5.5% TG group) value.
  • Furthermore, incidences and multiplicity of hyperplasias and adenomas and/or adenocarcinomas were comparable across all DAG oil-treated groups.
  • In contrast, incidences of colon adenomas and/or adenocarcinomas were significantly increased in rats given 5.5% HOTG, and adenomas with MCTG, but not 5.5% HLTG, as compared to the 5.5% TG value.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728035.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Diglycerides; 0 / Triglycerides; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


68. Ma DF, Kondo T, Nakazawa T, Niu DF, Mochizuki K, Kawasaki T, Yamane T, Katoh R: Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. Hum Pathol; 2010 Nov;41(11):1550-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In immunohistochemistry, we observed diffuse immunopositivity of ADORA2B in 67% of colorectal adenocarcinomas (39/58), 17% of tubular adenomas (5/30), and 0% of normal colon glands (0/62).
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colorectal Neoplasms / pathology. Receptor, Adenosine A2B / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20619442.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetamides; 0 / Adenosine A2 Receptor Antagonists; 0 / Antineoplastic Agents; 0 / N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy)acetamide; 0 / Purines; 0 / RNA, Messenger; 0 / Receptor, Adenosine A2B
  •  go-up   go-down


69. Wada R: Proposal of a new hypothesis on the development of colorectal epithelial neoplasia: nonspecific inflammation--colorectal Paneth cell metaplasia--colorectal epithelial neoplasia. Digestion; 2009;79 Suppl 1:9-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal epithelial neoplasia (CR-EN), both adenoma and adenocarcinoma, may develop from the essential tubules of the colorectum.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colorectal Neoplasms / pathology. Paneth Cells / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19153484.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 19
  •  go-up   go-down


70. Tatsumi N, Mukaisho K, Mitsufuji S, Tatsumi Y, Sugihara H, Okanoue T, Hattori T: Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases. Dig Dis Sci; 2005 Sep;50(9):1741-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases.
  • The entity of serrated adenoma of the colorectum was first proposed in 1990, and it was characterized as epithelial neoplasia combining the architectural features of a hyperplastic polyp with the cytological features of an adenoma.
  • Over the past few years, various clinicopathological studies on serrated adenoma have been reported, but its histogenesis remains unclear.
  • Recently the existence of a "serrated neoplasia pathway" leading to malignancy, which is different from the so-called adenoma-carcinoma sequence, has been discussed.
  • Yao et al. reported that hyperplastic polyps and serrated adenomas share a common cell lineage with gastric differentiation.
  • To clarify the existence of the serrated neoplasia pathway, we performed immunohistochemical staining of cytokeratin 7 (CK7) and cytokeratin 20 (CK20), which are commonly used to determine the primary site of a metastatic lesion, and we examined the pattern of CK7/CK20 expression in various colorectal lesions including 44 serrated adenomas, 25 hyperplastic polyps, 20 traditional adenomas, and 48 carcinomas.
  • An obvious difference existed in the pattern of CK7/CK20 expression between the serrated lesions (hyperplastic polyps and serrated adenomas) and others.
  • The majority of serrated adenomas and hyperplastic polyps presented a CK7+/CK20+ pattern, whereas most conventional adenomas and adenocarcinomas expressed CK7-/CK20+.
  • Adenocarcinoma developing in serrated adenoma also presented a CK7+/CK20+ pattern.
  • Taken together with the present results, a distinct pathway of colorectal carcinogenesis must exist, which is different from the adenoma-carcinoma sequence.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. Biomarkers, Tumor / blood. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Intermediate Filament Proteins / biosynthesis. Keratins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] J Pathol. 2000 Mar;190(4):444-9 [10699993.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):427-47 [1371204.001]
  • [Cites] Acta Histochem. 1991;91(1):21-3 [1724863.001]
  • [Cites] J Gastroenterol. 2002;37(6):467-70 [12108682.001]
  • [Cites] Gut. 2002 Aug;51(2):200-6 [12117880.001]
  • [Cites] Mod Pathol. 2003 May;16(5):403-10 [12748245.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4878-81 [12941809.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Virchows Arch. 2001 Oct;439(4):512-22 [11710638.001]
  • [Cites] Ann N Y Acad Sci. 1985;455:282-306 [2417517.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1884-7 [12085180.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):567-80 [1696264.001]
  • [Cites] Am J Pathol. 1990 Mar;136(3):641-55 [1690512.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):611-6 [12065774.001]
  • [Cites] Histol Histopathol. 2002 Apr;17 (2):445-54 [11962749.001]
  • [Cites] Pathol Int. 2001 Mar;51(3):215-20 [11328539.001]
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] J Pathol. 1999 Apr;187(5):511-7 [10398114.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):758-63 [11937308.001]
  • [Cites] Pathology. 2002 Dec;34(6):548-55 [12555993.001]
  • [Cites] J Pathol. 1991 Oct;165(2):145-52 [1720817.001]
  • (PMID = 16133982.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


71. Nakayama T, Yamazumi K, Uemura T, Yoshizaki A, Yakata Y, Matsuu-Matsuyama M, Shichijo K, Sekine I: X radiation up-regulates the occurrence and the multiplicity of invasive carcinomas in the intestinal tract of Apc(min/+) mice. Radiat Res; 2007 Oct;168(4):433-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Apc(min/+) mouse, an animal model for human familial adenomatous polyposis (FAP), contains a truncating mutation in the APC gene and spontaneously develops intestinal adenomas.
  • Forty out of 77 (52%) X-irradiated Apc(min/+) mice developed adenocarcinomas that invaded the proprial muscle layer of the small intestine; 24 of 44 (55%) were in males, and 16 of 33 (49%) were in females.

  • MedlinePlus Health Information. consumer health - X-Rays.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903035.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


72. Klopfleisch R, Schütze M, Linzmann H, Brunnberg L, Gruber AD: Increased Derlin-1 expression in metastases of canine mammary adenocarcinomas. J Comp Pathol; 2010 Jan;142(1):79-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased Derlin-1 expression in metastases of canine mammary adenocarcinomas.
  • There is greater expression of Derl-1 mRNA in laser microdissected lymph node metastases of mammary adenocarcinomas than in non-neoplastic mammary gland tissue from the same dog.
  • Samples of primary mammary adenocarcinomas were collected from 54 dogs in addition to the nodal metastases of these tumours and intralymphatic neoplastic cells.
  • Samples of mammary adenomas were collected from a further 44 dogs in addition to non-neoplastic mammary gland from the same animals.
  • Weak Derl-1 expression was found in non-neoplastic gland and mammary adenomas, moderate expression in adenocarcinomas, moderate to marked expression in lymph node metastases and marked expression in intralymphatic tumour cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Dog Diseases / metabolism. Mammary Neoplasms, Animal / metabolism. Membrane Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632687.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins
  •  go-up   go-down


73. Pezzoli A, Matarese V, Rubini M, Simoni M, Caravelli GC, Stockbrugger R, Cifalà V, Boccia S, Feo C, Simone L, Trevisani L, Liboni A, Gullini S: Colorectal cancer screening: results of a 5-year program in asymptomatic subjects at increased risk. Dig Liver Dis; 2007 Jan;39(1):33-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenomas and cancers were found in 122 (21.7%) and 12 (2.1%) subjects, respectively.
  • Histological examination in 181 persons with lesions (32.8%) showed (most serious lesion quoted) 47 hyperplastic polyps (26% of all lesions), 2 serrated adenomas (1.1%), 68 tubular adenomas (48%), 24 tubulovillous adenomas (13.3%), 9 adenomas with high grade dysplasia (5%) and 12 adenocarcinomas (6.6%).
  • [MeSH-minor] Adenoma / diagnosis. Colonoscopy. Female. Humans. Male. Middle Aged. Pedigree. Predictive Value of Tests. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17049323.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


74. Civit T, Klein O, Baylac F: [Lacrimal gland epithelial tumors]. Neurochirurgie; 2010 Apr-Jun;56(2-3):152-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic adenomas have a good prognosis if surgery achieves en bloc removal distant from the tumoral capsule.
  • Nevertheless, despite more severe treatment, the average survival remains limited for adenocarcinomas and cylindromas.
  • [MeSH-minor] Adenoma / pathology. Adenoma / radiography. Adenoma / surgery. Adult. Female. Humans. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20303130.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


75. Wang Y, Zhou ZG, Xia QJ, Zhang WY, Li HG, Wang R: [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Sep;11(5):465-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance].
  • OBJECTIVE: To investigate the expression differences of minichromosome maintenance 2 (MCM2) mRNA and protein among colon adenocarcinoma, colon adenoma and normal mucosa, and among different clinicopathological types of adenomas.
  • METHODS: Fifty specimens, including 33 colonic adenomas, 12 colonic adenocarcinomas and 5 normal colonic mucosa were selected.
  • Expression differences of MCM2 mRNA among the colonic adenocarcinoma, adenoma and normal colonic mucosa were evaluated by REST-XL software.
  • RESULTS: The expression of MCM2 was observed in the basal third to half of the colonic crypts in normal mucosa, while throughout the epithelium in the colonic adenocarcinomas and adenomas.
  • However, the expression of MCM2 mRNA in the adenocarcinomas was significantly higher than that in the adenomas(P=0.001).
  • The MCM2 mRNA expression was elevated in the adenoma with villous type, in the conditions of high-grade dysplasia, larger size, sessile morphology and in patients of older ages, but the difference was not significant by REST-XL (P>0.05).
  • CONCLUSION: The difference of MCM2 expression between the adenoma and the adenocarcinoma indicates its potential value in the early diagnosis of colonic cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Cell Cycle Proteins / metabolism. Colonic Neoplasms / metabolism. Nuclear Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803052.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


76. Feng Y, Bommer GT, Zhai Y, Akyol A, Hinoi T, Winer I, Lin HV, Cadigan KM, Cho KR, Fearon ER: Drosophila split ends homologue SHARP functions as a positive regulator of Wnt/beta-catenin/T-cell factor signaling in neoplastic transformation. Cancer Res; 2007 Jan 15;67(2):482-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that SHARP gene and protein expression is elevated in human colon and ovarian endometrioid adenocarcinomas and mouse colon adenomas and carcinomas carrying gene defects leading to beta-catenin dysregulation.
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Animals. HCT116 Cells. Humans. Mice. Mice, Transgenic. Signal Transduction. Transcriptional Activation

  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234755.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA082223; United States / NCI NIH HHS / CA / CA085463; United States / NCI NIH HHS / CA / CA094172
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Nuclear Proteins; 0 / SPEN protein, human; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


77. Lee SY, Chung H, Devaraj B, Iwaizumi M, Han HS, Hwang DY, Seong MK, Jung BH, Carethers JM: Microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasias. Gastroenterology; 2010 Nov;139(5):1519-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We evaluated tumor samples from a cohort of patients that had 24 adenomas and 84 colorectal cancers.
  • RESULTS: Moderately differentiated adenocarcinomas and poorly differentiated adenocarcinomas had higher frequencies of EMAST (56.9% and 40.0%, respectively) than well-differentiated adenocarcinomas (12.5%) or adenomas (33.3%) (P = .040).
  • CONCLUSIONS: EMAST is acquired during progression of adenoma and well-differentiated carcinomas to moderately and poorly differentiated carcinomas; it correlates with nuclear heterogeneity for hMSH3.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] BJU Int. 2007 May;99(5):1031-5 [17233803.001]
  • [Cites] J Gastrointest Surg. 2010 Oct;14(10):1521-8 [20844976.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2008 Jul;18(3):581-93, xi [18674705.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2488-91 [10811129.001]
  • [Cites] Int J Cancer. 2001 Jan 15;91(2):200-4 [11146445.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7444-8 [11606378.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jul;283(1):C148-54 [12055083.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):4894-9 [12118368.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8699-706 [14647464.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1237-40 [8640805.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2509-13 [16380996.001]
  • [Cites] J Mol Med (Berl). 2006 Apr;84(4):329-33 [16416315.001]
  • [Cites] J Mol Med (Berl). 2006 Oct;84(10):833-41 [16924473.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8465-72 [18922920.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1079-99 [18773902.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:88 [19116039.001]
  • [Cites] Oncol Rep. 2010 Feb;23(2):551-61 [20043121.001]
  • [Cites] Fam Cancer. 2008;7(1):41-52 [17636426.001]
  • (PMID = 20708618.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067287; United States / NCI NIH HHS / CA / CA132384; United States / NCI NIH HHS / CA / U54 CA132384; United States / NIDDK NIH HHS / DK / R24 DK080506; United States / NCI NIH HHS / CA / CA132379; United States / NIDDK NIH HHS / DK / DK067287; United States / NCI NIH HHS / CA / U54 CA132379; United States / NIDDK NIH HHS / DK / DK080506
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MSH3 protein, human
  • [Other-IDs] NLM/ NIHMS229907; NLM/ PMC2967646
  •  go-up   go-down


78. Akatsu T, Aiura K, Shimazu M, Ueda M, Wakabayashi G, Tanabe M, Kawachi S, Kitajima M: Can endoscopic ultrasonography differentiate nonneoplastic from neoplastic gallbladder polyps? Dig Dis Sci; 2006 Feb;51(2):416-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study aimed to clarify the endoscopic ultrasonography (EUS) features of nonneoplastic (cholesterol polyps and adenomyomatosis) and neoplastic (adenoma and adenocarcinoma) gallbladder polyps and to evaluate the effectiveness and limitation of EUS in the differential diagnosis of these lesions.
  • However, three of nine neoplastic lesions (three adenomas and six adenocarcinomas) showed one of these signs due to concomitant cholesterosis (n = 2) or proliferated Rokitansky-Aschoff sinuses (n = 1).
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Adenoma / diagnostic imaging. Endosonography. Gallbladder Diseases / diagnostic imaging. Gallbladder Neoplasms / diagnostic imaging. Polyps / diagnostic imaging

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1985 Sep;72(9):728-30 [3899247.001]
  • [Cites] J Gastroenterol. 1996 Jun;31(3):470-4 [8726845.001]
  • [Cites] Br J Surg. 2000 Apr;87(4):414-7 [10759734.001]
  • [Cites] Br J Surg. 1992 Mar;79(3):227-9 [1555088.001]
  • [Cites] Am J Gastroenterol. 1988 Jun;83(6):670-4 [3376922.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2226-34 [7127263.001]
  • [Cites] Lancet. 1997 Mar 22;349(9055):817 [9121250.001]
  • [Cites] Surgery. 1991 Jan;109(1):107-10 [1984629.001]
  • [Cites] Am J Surg. 2001 Jan;181(1):65-70 [11248179.001]
  • [Cites] Am J Gastroenterol. 1989 Nov;84(11):1386-90 [2683741.001]
  • [Cites] Br J Surg. 1990 Apr;77(4):363-4 [2187556.001]
  • [Cites] World J Surg. 1999 Jul;23 (7):708-12 [10390591.001]
  • [Cites] Gastroenterol Jpn. 1981;16(2):134-40 [7227765.001]
  • [Cites] Am J Gastroenterol. 1992 May;87(5):630-3 [1595653.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):657-60 [11685029.001]
  • [Cites] Scand J Gastroenterol. 1990 Mar;25(3):281-6 [2320947.001]
  • [Cites] Endoscopy. 2002 Dec;34(12 ):959-65 [12471539.001]
  • [Cites] Arch Surg. 1988 Jan;123(1):26-9 [3276295.001]
  • [Cites] Arch Pathol. 1970 Nov;90(5):423-32 [4319984.001]
  • [Cites] Gastrointest Endosc. 2000 Sep;52(3):372-9 [10968853.001]
  • [Cites] Gut. 1996 Dec;39(6):860-2 [9038670.001]
  • [Cites] Am J Gastroenterol. 1997 Nov;92 (11):2066-8 [9362194.001]
  • [Cites] Acta Pathol Jpn. 1993 Jan-Feb;43(1-2):82-5 [8465661.001]
  • [Cites] Am J Gastroenterol. 1986 Jan;81(1):61-6 [3942125.001]
  • (PMID = 16534690.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Cekanova M, Lee SH, Donnell RL, Sukhthankar M, Eling TE, Fischer SM, Baek SJ: Nonsteroidal anti-inflammatory drug-activated gene-1 expression inhibits urethane-induced pulmonary tumorigenesis in transgenic mice. Cancer Prev Res (Phila); 2009 May;2(5):450-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urethane-induced pulmonary adenomas and adenocarcinomas were observed in control mice; however, only pulmonary adenomas were observed in NAG-1(Tg+/FVB) mice.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 2005 Feb;67(2):356-64 [15509713.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2425-32 [15308587.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18636-42 [15757899.001]
  • [Cites] Circulation. 2005 May 17;111(19):2494-502 [15867183.001]
  • [Cites] Lung Cancer. 2005 Jul;49(1):35-45 [15949588.001]
  • [Cites] Am J Pathol. 2005 Dec;167(6):1763-75 [16314486.001]
  • [Cites] Prog Lipid Res. 2006 Jan;45(1):1-16 [16337272.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1352-61 [16731769.001]
  • [Cites] Apoptosis. 2006 Jul;11(7):1131-8 [16699947.001]
  • [Cites] J Cell Physiol. 2006 Sep;208(3):566-74 [16741990.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1553-60 [17101328.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1164-73 [17315157.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6863-71 [17638897.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Nov;323(2):746-56 [17715378.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9 [18000061.001]
  • [Cites] Exp Cell Res. 2008 Mar 10;314(5):1105-14 [18062963.001]
  • [Cites] Mol Carcinog. 2008 Mar;47(3):197-208 [18058799.001]
  • [Cites] Int J Oncol. 2008 Apr;32(4):809-19 [18360708.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1174-86 [18375740.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):175-82 [10623665.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):543-50 [10753183.001]
  • [Cites] Trends Biochem Sci. 2000 Jun;25(6):257-60 [10838561.001]
  • [Cites] J Biol Chem. 2000 Jun 30;275(26):20127-35 [10777512.001]
  • [Cites] Mol Pharmacol. 2001 Apr;59(4):901-8 [11259636.001]
  • [Cites] Carcinogenesis. 2002 Mar;23(3):425-34 [11895857.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1388-98 [11984525.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5845-53 [12475986.001]
  • [Cites] Mol Pharmacol. 2003 Mar;63(3):557-64 [12606762.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):6883-92 [14662774.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4266s-4269s [15217972.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1517-24 [15033900.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11514-9 [9326641.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):49617-23 [15377673.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 4;328(1):63-9 [15670751.001]
  • (PMID = 19401523.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108975-03; United States / NCI NIH HHS / CA / R01 CA108975; United States / NCI NIH HHS / CA / CA108975-03; United States / NCI NIH HHS / CA / R01 CA 108975; United States / NCI NIH HHS / CA / R01 CA108975-04; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / CA108975-01A2; United States / NCI NIH HHS / CA / R01 CA108975-02; United States / NCI NIH HHS / CA / R01 CA108975-01A2; United States / NCI NIH HHS / CA / CA108975-02; United States / NCI NIH HHS / CA / CA108975-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Growth Differentiation Factor 15; 3IN71E75Z5 / Urethane; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ NIHMS118668; NLM/ PMC2697576
  •  go-up   go-down


80. Bongers G, Maussang D, Muniz LR, Noriega VM, Fraile-Ramos A, Barker N, Marchesi F, Thirunarayanan N, Vischer HF, Qin L, Mayer L, Harpaz N, Leurs R, Furtado GC, Clevers H, Tortorella D, Smit MJ, Lira SA: The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest; 2010 Nov;120(11):3969-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VS28 mice showed a hyperplastic intestinal epithelium and, strikingly, developed adenomas and adenocarcinomas by 40 weeks of age.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):741-50 [9049319.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):445-54 [10662790.001]
  • [Cites] J Biol Chem. 2000 Nov 3;275(44):34183-9 [10940307.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1133-7 [11050102.001]
  • [Cites] J Virol. 2001 Jul;75(13):5949-57 [11390596.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3347-50 [12067971.001]
  • [Cites] Cytokine. 2002 Jul 7;19(1):37-46 [12200112.001]
  • [Cites] Lancet. 2002 Nov 16;360(9345):1557-63 [12443594.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):23-36 [12559173.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Pharmacol Ther. 2003 Jun;98(3):269-97 [12782241.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1311-9 [14598247.001]
  • [Cites] Hum Pathol. 2003 Dec;34(12):1331-6 [14691920.001]
  • [Cites] Neuropsychopharmacology. 2004 Mar;29(3):441-9 [14628000.001]
  • [Cites] FEMS Microbiol Rev. 2004 Feb;28(1):59-77 [14975530.001]
  • [Cites] Cancer Lett. 2004 Aug 10;211(2):243-7 [15219948.001]
  • [Cites] J Immunol. 1997 Jul 1;159(1):401-8 [9200479.001]
  • [Cites] Carcinogenesis. 1998 Apr;19(4):543-9 [9600336.001]
  • [Cites] J Exp Med. 1998 Sep 7;188(5):855-66 [9730887.001]
  • [Cites] FEBS Lett. 1998 Dec 18;441(2):209-14 [9883886.001]
  • [Cites] Annu Rev Cell Dev Biol. 1998;14:59-88 [9891778.001]
  • [Cites] J Biol Chem. 1999 Mar 5;274(10):6476-82 [10037740.001]
  • [Cites] J Gen Virol. 1999 Mar;80 ( Pt 3):543-7 [10091991.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):331-6 [10433925.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):244-9 [15842049.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):322-7 [15863380.001]
  • [Cites] Int Immunol. 2005 Aug;17(8):1023-34 [16000328.001]
  • [Cites] FEBS J. 2005 Aug;272(16):4163-77 [16098198.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2537-48 [16219459.001]
  • [Cites] Trends Pharmacol Sci. 2006 Jan;27(1):56-63 [16352349.001]
  • [Cites] J Intern Med. 2006 Mar;259(3):219-46 [16476101.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13068-73 [16924106.001]
  • [Cites] Cell Cycle. 2006 Oct;5(20):2295-300 [17035736.001]
  • [Cites] J Neurovirol. 2007;13(1):85; author reply 86-7 [17454453.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1133-9 [17341657.001]
  • [Cites] Nat Protoc. 2007;2(8):1998-2004 [17703211.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Gastroenterology. 2008 Mar;134(3):849-64 [18325394.001]
  • [Cites] Rev Inst Med Trop Sao Paulo. 2008 Mar-Apr;50(2):83-7 [18488086.001]
  • [Cites] J Cell Physiol. 2008 Aug;216(2):378-88 [18338378.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):539-41 [18669440.001]
  • [Cites] Neoplasia. 2009 Jan;11(1):1-9 [19107226.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):780-98 [19263594.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2861-9 [19318580.001]
  • [Cites] Gastroenterology. 2009 May;136(5):1680-8.e7 [19208363.001]
  • [Cites] Virology. 2009 Sep 15;392(1):1-10 [19720205.001]
  • [Cites] Mol Pharmacol. 2009 Oct;76(4):692-701 [19570946.001]
  • [Cites] Lancet. 1978 May 6;1(8071):957-60 [76890.001]
  • [Cites] Intervirology. 1979;12(2):84-8 [231587.001]
  • [Cites] Intervirology. 1980;14(3-4):223-7 [7239857.001]
  • [Cites] Int J Cancer. 1981 May 15;27(5):659-67 [6270021.001]
  • [Cites] Gut. 1982 Jan;23(1):21-30 [6276266.001]
  • [Cites] Intervirology. 1981;16(4):244-9 [6282775.001]
  • [Cites] Klin Wochenschr. 1985 May 2;63(9):405-8 [2987605.001]
  • [Cites] Gut. 1985 Oct;26(10):1053-8 [2996990.001]
  • [Cites] Dig Dis Sci. 1988 Jun;33(6):741-50 [2836142.001]
  • [Cites] Science. 1990 Feb 2;247(4942):561-4 [1689075.001]
  • [Cites] Cell. 1993 Feb 12;72(3):415-25 [7679328.001]
  • [Cites] J Biol Chem. 1994 Nov 18;269(46):28539-42 [7961796.001]
  • [Cites] Gastroenterology. 1995 Jan;108(1):40-50 [7806062.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jun 6;211(1):325-30 [7540006.001]
  • [Cites] J Pathol. 1996 Feb;178(2):201-6 [8683390.001]
  • [Cites] Nature. 1997 Jan 23;385(6614):347-50 [9002520.001]
  • (PMID = 20978345.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122665002; United States / NIDDK NIH HHS / DK / P01 DK072201; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ORF74 protein, Human herpesvirus 8; 0 / Receptors, Chemokine; 0 / US28 receptor, Cytomegalovirus; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2964974
  •  go-up   go-down


81. Darling MR, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 6 expression in salivary gland tumors. J Histochem Cytochem; 2006 Mar;54(3):337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic adenomas (PA), adenoid cystic carcinomas, polymorphous low-grade adenocarcinomas, acinic cell carcinomas, mucoepidermoid carcinomas, and adenocarcinomas not otherwise specified of both minor and major salivary glands were examined.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286664.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


82. Mönkemüller K, Fry LC, Ebert M, Bellutti M, Venerito M, Knippig C, Rickes S, Muschke P, Röcken C, Malfertheiner P: Feasibility of double-balloon enteroscopy-assisted chromoendoscopy of the small bowel in patients with familial adenomatous polyposis. Endoscopy; 2007 Jan;39(1):52-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND STUDY AIMS: Patients with familial adenomatous polyposis (FAP) are at increased risk of developing duodenal and jejunal adenocarcinomas.
  • Small-bowel polyps (including papillary adenomas) were detected in seven patients (88 %).
  • In one patient the polyps were flat and only visible with chromoendoscopy (biopsy confirmed these to be adenomas).
  • [MeSH-minor] Adenoma. Adolescent. Adult. Feasibility Studies. Female. Humans. Male. Middle Aged. Prospective Studies


83. Vargas PA, Cheng Y, Barrett AW, Craig GT, Speight PM: Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours. J Oral Pathol Med; 2008 May;37(5):309-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 13 adenoid cystic carcinomas (ACC), 10 carcinoma ex pleomorphic adenomas (CEPA), 10 mucoepidermoid carcinomas (MEC), 10 polymorphous low-grade adenocarcinomas (PLGA), 10 pleomorphic adenomas (PA) and nine acinic cell carcinomas (AcCC).
  • Further studies are warranted to assess the value of Mcm-2 as a predictor of recurrence and survival.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / metabolism. Cell Proliferation. Diagnosis, Differential. Female. Geminin. Humans. Immunoenzyme Techniques. Male. Microarray Analysis. Middle Aged. Minichromosome Maintenance Complex Component 2. Neoplasm Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248354.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


84. Coons SW, Estrada SI, Gamez R, White WL: Cytokeratin CK 7 and CK 20 expression in pituitary adenomas. Endocr Pathol; 2005;16(3):201-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin CK 7 and CK 20 expression in pituitary adenomas.
  • However, we recently reported the use of CK 7/20 expression to document malignant progression and metastasis of a pituitary tumor, indicating the potential diagnostic usefulness of the CK 7/20 profile of pituitary adenomas.
  • We analyzed CK 7/20 expression in 97 pituitary adenomas subclassified by immunohistochemical hormone expression.
  • Corticotrophs and sparsely granulated growth hormone-positive adenomas were consistently CK 20 positive (and CK 7 negative) whereas all other subtypes were almost always CK 20 negative.
  • This CK 20-positive, CK 7-negative profile is previously described consistently only in colonic adenocarcinomas.
  • This study documents that subtypes of pituitary adenomas have different CK 7/20 profiles.
  • Whereas this pattern is likely to have diagnostic usefulness in only rare adenomas, the presence of a unique CK signature in corticotrophs and sparsely granulated growth hormone-positive adenomas, subtypes particularly noted for invasive and aggressive behavior, merits further investigation.
  • [MeSH-major] Adenoma / metabolism. Biomarkers, Tumor / metabolism. Intermediate Filament Proteins / metabolism. Keratins / metabolism. Pituitary Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):870-6 [10843291.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):13-43, v-vi [10207684.001]
  • [Cites] Am J Clin Pathol. 1994 Dec;102(6):764-7 [7528468.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):119-26 [9490269.001]
  • [Cites] Mod Pathol. 1995 May;8(4):384-8 [7567935.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):171-7 [9921990.001]
  • [Cites] Endocr Pathol. 1996 Summer;7(2):145-150 [12114642.001]
  • (PMID = 16299403.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CAM 5.2 antigen; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


85. Onishi M, Saito M, Sokuza Y, Mori C, Nishikawa T, Shimizu K, Sugata E, Tsujiuchi T: Numerical changes in the mitochondrial DNA displacement loop in lung lesions induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Mutat Res; 2008 Feb 1;638(1-2):133-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eleven out of 24 hyperplasias (45.6%), 8 out of 16 adenomas (50.0%), and 14 out of 21 adenocarcinomas (66.7%) showed numerical changes, in a polymeric C-tract at positions 16,086-16,092 of the mtDNA D-loop, with a one base insertion of cytosine increasing the length of the C-tract, from the seven nucleotides observed in normal lung tissues from non-BHP treated rats, to eight.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / genetics. Adenoma / chemically induced. Adenoma / genetics. Animals. Hyperplasia / chemically induced. Hyperplasia / genetics. Lung / pathology. Male. Mutagens / pharmacology. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964613.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / Mutagens; 0 / Nitrosamines; 53609-64-6 / diisopropanolnitrosamine
  •  go-up   go-down


86. Lim SC, Oh SH: The role of CD24 in various human epithelial neoplasias. Pathol Res Pract; 2005;201(7):479-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors aimed at evaluating CD24 protein expression in adenoma and adenocarcinoma of the stomach, colon, gallbladder, ovary, and breast to establish a correlation with clinicopathologic data.
  • The present study clearly demonstrates that CD24 is abundantly expressed in adenocarcinoma compared to adenoma of the colon and breast.
  • Intracytoplasmic CD24 expression was found to be highly associated with adenocarcinoma of the colon, gallbladder, and ovary compared to the adenoma group of those organs, and with the positive nodal status compared to the negative nodal status of the colonic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Antigens, CD / biosynthesis. Biomarkers, Tumor / analysis. Membrane Glycoproteins / biosynthesis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164042.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD24; 0 / Biomarkers, Tumor; 0 / CD24 protein, human; 0 / Membrane Glycoproteins
  •  go-up   go-down


87. Han YD, Hong YK, Kang JG, Choi YJ, Park CH: Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis. J Korean Soc Coloproctol; 2010 Oct;26(5):339-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis.
  • METHODS: Fifty colorectal adenomas and forty adenocarcinomas were investigated by using immunohistochemical staining for COX-2, VEGF and EGFR.
  • The correlations of COX-2, VEGF and EGFR with the grade of dysplasia, the size of the adenoma, and various clinicopathologic factors were studied.
  • COX-2 and EGFR showed correlations with adenomas rather than adenocarcinomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21152137.001).
  • [ISSN] 2093-7830
  • [Journal-full-title] Journal of the Korean Society of Coloproctology
  • [ISO-abbreviation] J Korean Soc Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2998021
  • [Keywords] NOTNLM ; Adenocarcinoma / Colorectal carcinoma / Cyclooxygenase 2 / Endothelial growth factor receptor / Vascular endothelial growth factor
  •  go-up   go-down


88. Likhin FA, Bartnovskiĭ AE, Vdovichenko KK, Abramov AA, Belokhvostov AS: [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma]. Urologiia; 2005 Jul-Aug;(4):12-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma].
  • Blood plasm and cellur urinary precipitate DNA was investigated in patients with prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. DNA, Neoplasm / analysis. Polymerase Chain Reaction / methods. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158738.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA
  •  go-up   go-down


89. Platell C: Transanal endoscopic microsurgery. ANZ J Surg; 2009 Apr;79(4):275-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology indicated 128 adenomas, 52 carcinomas in situ, and 52 adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Carcinoma in Situ / surgery. Colonoscopy / statistics & numerical data. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432714.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


90. Terhaar Sive Droste JS, Craanen ME, van der Hulst RW, Bartelsman JF, Bezemer DP, Cappendijk KR, Meijer GA, Morsink LM, Snel P, Tuynman HA, van Wanrooy RL, Wesdorp EI, Mulder CJ: Colonoscopic yield of colorectal neoplasia in daily clinical practice. World J Gastroenterol; 2009 Mar 7;15(9):1085-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced neoplasm was defined as adenoma > 10 mm in size, with > 25% villous features or with high-grade dysplasia or cancer.
  • The prevalence of advanced neoplasia was 13%, with 281 (6%) adenocarcinomas and 342 (7%) advanced adenomas.
  • Of all patients with right-sided advanced neoplasia (n = 228), 51% had a normal distal colon, whereas 27% had a synchronous distal adenoma.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adenoma / diagnosis. Adenoma / epidemiology. Adenoma / pathology. Anemia / etiology. Colon / anatomy & histology. Colon / pathology. Functional Laterality. Humans. Netherlands / epidemiology. Prevalence. Weight Loss

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Jun;51(6):647-51 [10840294.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):941-7 [17140902.001]
  • [Cites] Scand J Gastroenterol. 2002 May;37(5):568-73 [12059059.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):660-3 [12101114.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):608-14 [12612899.001]
  • [Cites] JAMA. 2003 Dec 10;290(22):2959-67 [14665657.001]
  • [Cites] Ann Intern Med. 2003 Dec 16;139(12):959-65 [14678915.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):777-81 [14999789.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(5):638-42 [15010063.001]
  • [Cites] Am J Gastroenterol. 2004 Mar;99(3):472-7 [15056088.001]
  • [Cites] Ann Intern Med. 2004 Aug 17;141(4):264-71 [15313742.001]
  • [Cites] J Clin Pathol. 1982 Aug;35(8):830-41 [7107955.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] Am J Gastroenterol. 1995 Mar;90(3):353-65 [7872270.001]
  • [Cites] Gastrointest Endosc. 1997 Dec;46(6):492-6 [9434214.001]
  • [Cites] Eur J Cancer Prev. 2004 Aug;13(4):257-62 [15554552.001]
  • [Cites] Cell Oncol. 2005;27(1):17-29 [15750204.001]
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):547-53 [15812407.001]
  • [Cites] J Med Screen. 2005;12(1):28-32 [15814016.001]
  • [Cites] Lancet Oncol. 2005 Nov;6(11):871-6 [16257795.001]
  • [Cites] Gastrointest Endosc. 2005 Dec;62(6):875-83 [16301030.001]
  • [Cites] JAMA. 2006 May 24;295(20):2357-65 [16720821.001]
  • [Cites] Gastrointest Endosc. 2006 Nov;64(5):751-9 [17055869.001]
  • [Cites] N Engl J Med. 2006 Nov 2;355(18):1863-72 [17079760.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2533-41 [17167136.001]
  • [Cites] Cell Oncol. 2007;29(1):19-24 [17429138.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2106-14 [18183593.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Colorectal Dis. 2008 Sep;10(7):708-14 [17956587.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Mar;26(3):220-4 [11981461.001]
  • (PMID = 19266601.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2655182
  •  go-up   go-down


91. Zitt M, Zitt M, Müller HM: DNA methylation in colorectal cancer--impact on screening and therapy monitoring modalities? Dis Markers; 2007;23(1-2):51-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It arises from benign neoplasms and evolves into adenocarcinomas through a stepwise histological progression sequence, proceeding from either adenomas or hyperplastic polyps/serrated adenomas.
  • Genetic alterations have been associated with specific steps in this adenoma-carcinoma sequence and are believed to drive the histological progression of CRC.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325426.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 160
  • [Other-IDs] NLM/ PMC3851076
  •  go-up   go-down


92. Chang H, Su JM, Huang CC, Liu LC, Tsai CH, Chou MC, Lin P: Using a combination of cytochrome P450 1B1 and beta-catenin for early diagnosis and prevention of colorectal cancer. Cancer Detect Prev; 2005;29(6):562-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although fecal occult blood test and invasive endoscopic examination are common used to detect colorectal adenomas and cancers, non-invasive and specific biomarkers are still under investigation.
  • METHODS: These biomarkers were analyzed semi-quantified across 231 colonic tissues including 97 adenocarcinomas, 85 adenomas and 49 non-neoplastic colons using immunohistochemistry.
  • In order to differentiate non-neoplastic colons from colorectal neoplasms (adenoma and carcinoma), the values for CYP1B1, AhR, nuclear beta-catenin, p53 and bcl-2 expressions were subjected to discrimination analysis, then the cross-validation, sensitivity and specificity of these models were calculated.
  • The overexpression rates for CYP1B1, p53, nuclear beta-catenin and bcl-2 were significantly higher in the adenoma and carcinoma groups than in the non-neoplastic colon group (p<0.05).
  • CONCLUSIONS: The increase in expression of CYP1B1 occurred not only in colorectal carcinoma and but also in adenoma.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / prevention & control. Adenoma / diagnosis. Adenoma / metabolism. Adenoma / prevention & control. Adult. Aged. Aged, 80 and over. Early Diagnosis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Receptors, Aryl Hydrocarbon / biosynthesis. Sensitivity and Specificity. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289386.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Aryl Hydrocarbon; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; EC 1.14.15.4 / Steroid 11-beta-Hydroxylase
  •  go-up   go-down


93. Kerbel RS, Benezra R, Lyden DC, Hattori K, Heissig B, Nolan DJ, Mittal V, Shaked Y, Dias S, Bertolini F, Rafii S: Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proc Natl Acad Sci U S A; 2008 Aug 26;105(34):E54; author reply E55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas.
  • [MeSH-major] Adenocarcinoma / pathology. Endothelial Cells / pathology. Neovascularization, Pathologic / pathology
  • [MeSH-minor] Adenoma / pathology. Animals. Humans. Mice. Neoplasm Metastasis / pathology. Stem Cells / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 2005 Nov 8;112(19):2951-8 [16275883.001]
  • [Cites] Blood. 2003 Jan 1;101(1):168-72 [12393704.001]
  • [Cites] Nat Med. 2005 Mar;11(3):261-2 [15723071.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6620-5 [18443294.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18111-6 [16326806.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):835-45 [17036040.001]
  • [Cites] Science. 2008 Jan 11;319(5860):195-8 [18187653.001]
  • [CommentOn] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6620-5 [18443294.001]
  • (PMID = 18715995.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2527966
  •  go-up   go-down


94. Dixon E, Vollmer CM Jr, Sahajpal A, Cattral MS, Grant DR, Taylor BR, Langer B, Gallinger S, Greig PD: Transduodenal resection of peri-ampullary lesions. World J Surg; 2005 May;29(5):649-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathology of the lesions was as follows: 11 with benign ampullary adenomas, including 4 with familial adenomatous polyposis (FAP); 7 with peri-ampullary adenocarcinomas; and 1 with a benign stricture.
  • The specificity and positive predictive value of the intraoperative histology were both 100%, and the sensitivity and negative predictive value were 57% and 38%, respectively.
  • Three of the 4 patients with FAP have recurrent adenomatous change; 2 of the 7 with carcinoma have metastatic adenocarcinoma.
  • Transduodenal resection of peri-ampullary lesions appears to be a safe alternative to radical resection for benign adenomas and selected carcinoma.
  • Intraoperative frozen section assessment is recommended in cases of potential adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Digestive System Surgical Procedures

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1996 Apr;131(4):366-71 [8615720.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):621-7 [8916877.001]
  • [Cites] Dis Colon Rectum. 1996 Apr;39(4):384-7 [8878496.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:201-3 [10436822.001]
  • [Cites] Surgery. 2000 Jun;127(6):628-33 [10840357.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):13-21, discussion 22-3 [10631358.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] J Gastrointest Surg. 2002 Sep-Oct;6(5):770-5 [12399068.001]
  • [Cites] Dis Colon Rectum. 1999 Dec;42(12):1533-6 [10613470.001]
  • (PMID = 15827855.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Nagamine CM, Rogers AB, Fox JG, Schauer DB: Helicobacter hepaticus promotes azoxymethane-initiated colon tumorigenesis in BALB/c-IL10-deficient mice. Int J Cancer; 2008 Feb 15;122(4):832-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The BALB/c-IL10 null mouse strain develops colitis and colitis-associated adenocarcinomas, and is a model for idiopathic inflammatory bowel disease.
  • We tested the hypotheses that (i) azoxymethane (AOM), a carcinogen that targets the colon, synergizes with the colonic inflammation inherent in the BALB/c-IL10 null mouse resulting in an increase in incidence, multiplicity and/or progression of AOM-induced tumors or colitis-associated adenocarcinomas; and (ii) prior infection with Helicobacter hepaticus, a common enterohepatic bacterial pathogen in many research mouse colonies, increases the incidence, multiplicity and/or progression of AOM-induced colon tumors or colitis-associated adenocarcinomas in the BALB/c-IL10 null mouse.
  • No colitis-associated adenocarcinomas were identified.
  • Infection with H. hepaticus prior to AOM-treatment also did not result in colitis-associated adenocarcinomas but did result in a significant increase in the incidence of AOM-induced colon tumors relative to AOM treatment alone.
  • The AOM-induced adenomas were predominantly exophytic and nodular or polypoid and localized to the distal colon.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Adenocarcinoma / virology. Animals. Colitis / chemically induced. Colitis / pathology. Colitis / virology. Interleukin-10 / genetics. Interleukin-10 / physiology. Mice. Mice, Inbred BALB C. Mice, Knockout

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17957786.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES002109; United States / NCI NIH HHS / CB / N02-CB-07008; United States / NCI NIH HHS / CA / P01 CA26731; United States / NIDDK NIH HHS / DK / R01 DK52413; United States / NCRR NIH HHS / RR / T32 RR07036
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 130068-27-8 / Interleukin-10; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


96. Sparr JA, Bandipalliam P, Redston MS, Syngal S: Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol; 2009 Feb;33(2):309-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phenotypic manifestations of Lynch syndrome in this patient included multiple adenomas and adenocarcinomas of the colon and also several other Lynch syndrome-associated cancers.
  • The patient's adenocarcinoma of the colon and IPMN of the pancreas showed identical immunohistochemical staining profiles with loss of expression of MSH2 and MSH6 proteins and high levels of microsatellite instability.
  • The immunohistochemical staining and microsatellite instability patterns of the adenocarcinoma of the colon and IPMN gives strong evidence to support the consideration of IPMN as part of the spectrum of lesions found in Lynch syndrome.

  • Genetic Alliance. consumer health - Lynch syndrome.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Genet. 1999 Nov;36(11):801-18 [10544223.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):444-9 [18398828.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3139-44 [11306499.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):537-42 [12808058.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):235-8 [14760534.001]
  • [Cites] Br J Cancer. 1985 Aug;52(2):271-3 [4027169.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):1109-12 [1913482.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):677-85 [8431847.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1501-7 [9626054.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):97-101 [15623495.001]
  • [Cites] Arch Surg. 2006 Jan;141(1):51-6; discussion 56 [16415411.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1498-502 [16996571.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):803-13; discussion 813-4 [17481488.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • (PMID = 18987546.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA113433; United States / NCI NIH HHS / CA / K24 CA113433-04; United States / PHS HHS / / K24-113433
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  • [Other-IDs] NLM/ NIHMS77744; NLM/ PMC2631097
  •  go-up   go-down


97. St Hill CA, Farooqui M, Mitcheltree G, Gulbahce HE, Jessurun J, Cao Q, Walcheck B: The high affinity selectin glycan ligand C2-O-sLex and mRNA transcripts of the core 2 beta-1,6-N-acetylglucosaminyltransferase (C2GnT1) gene are highly expressed in human colorectal adenocarcinomas. BMC Cancer; 2009 Mar 06;9:79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The high affinity selectin glycan ligand C2-O-sLex and mRNA transcripts of the core 2 beta-1,6-N-acetylglucosaminyltransferase (C2GnT1) gene are highly expressed in human colorectal adenocarcinomas.
  • Our goal was to determine the expression profiles of C2-O-sLex in the malignant progression and metastasis of colorectal adenocarcinomas.
  • Using CHO-131 mAb, we investigated whether C2-O-sLex was present in 113 human primary colorectal adenocarcinomas, 10 colorectal adenomas, 46 metastatic liver tumors, 28 normal colorectal tissues, and 5 normal liver tissues by immunohistochemistry.
  • We also examined mRNA levels of the enzyme core 2 beta1,6-N-acetylglucosaminyltransferase (C2GnT1) in 20 well, 15 moderately, and 2 poorly differentiated colorectal adenocarcinomas, and in 5 normal colorectal tissues by using quantitative real-time polymerase chain reactions (RT-PCR).
  • RESULTS: We observed high reactivity with CHO-131 mAb in approximately 70% of colorectal carcinomas and 87% of metastatic liver tumors but a lack of reactivity in colorectal adenomas and normal colonic and liver tissues.
  • Positive reactivity with CHO-131 mAb was very prominent in neoplastic colorectal glands of well to moderately differentiated adenocarcinomas.
  • The most intense staining with CHO-131 mAb was observed at the advancing edge of tumors with the deepest invasive components.Finally, we analyzed C2GnT1 mRNA levels in 37 colorectal adenocarcinomas and 5 normal colorectal tissues by RT-PCR.
  • Significantly, we observed a greater than 15-fold increase in C2GnT1 mRNA levels in colorectal adenocarcinomas compared to normal colorectal tissues.
  • CONCLUSION: C2-O-sLex, detected by the CHO-131 mAb, is a tumor associated antigen whose expression is highly upregulated in colorectal adenocarcinomas and metastatic liver tumors compared to normal tissues.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosci Lett. 2003 Mar 13;339(1):62-6 [12618301.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):26391-400 [12736247.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1303-6 [2588007.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Mar;87(5):1673-7 [1689848.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13771-6 [10570148.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):11-24 [10636097.001]
  • [Cites] Science. 1990 Nov 23;250(4984):1132-5 [1701275.001]
  • [Cites] Lab Invest. 1992 Mar;66(3):324-30 [1371572.001]
  • [Cites] J Cell Biol. 1992 May;117(4):895-902 [1374413.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9326-330 [1329093.001]
  • [Cites] Cancer Res. 1993 Jan 15;53(2):354-61 [7678075.001]
  • [Cites] J Exp Med. 1993 Mar 1;177(3):657-66 [7679706.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2978-86 [7684623.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3632-7 [8101764.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2323-30 [8104679.001]
  • [Cites] Semin Cancer Biol. 1993 Oct;4(5):319-24 [7903054.001]
  • [Cites] Immunology. 1994 Feb;81(2):303-8 [7512530.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):901-7 [7515860.001]
  • [Cites] Exp Cell Res. 1995 Jan;216(1):215-21 [7529188.001]
  • [Cites] Cell Biophys. 1993 Aug-Dec;23(1-3):3-89 [7895250.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37987-97 [12847092.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):21984-91 [15026421.001]
  • [Cites] Int Surg. 2004 Apr-Jun;89(2):100-6 [15285243.001]
  • [Cites] Blood. 1983 Nov;62(5):1022-6 [6194834.001]
  • [Cites] Biochim Biophys Acta. 1985;780(2):119-50 [3890942.001]
  • [Cites] Cancer. 1986 May 1;57(9):1866-70 [3485470.001]
  • [Cites] Biol Chem Hoppe Seyler. 1988 Aug;369(8):661-5 [2905604.001]
  • [Cites] Cancer Res. 1989 Dec 15;49(24 Pt 1):6883-8 [2573422.001]
  • [Cites] Glycobiology. 1994 Dec;4(6):873-84 [7734850.001]
  • [Cites] Int J Cancer. 1995 May 16;61(4):455-60 [7538975.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4425-31 [7545541.001]
  • [Cites] J Invest Dermatol. 1996 Apr;106(4):611-5 [8617993.001]
  • [Cites] Gastroenterology. 1996 May;110(5):1354-67 [8613039.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1996 Feb;97(2):140-4 [8632742.001]
  • [Cites] J Biol Chem. 1996 Feb 9;271(6):3255-64 [8621728.001]
  • [Cites] Int J Cancer. 1996 Aug 22;69(4):290-4 [8797870.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5309-18 [8968075.001]
  • [Cites] Glycoconj J. 1996 Dec;13(6):1043-7 [8981096.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):816-25 [9053509.001]
  • [Cites] Dis Colon Rectum. 1997 Apr;40(4):420-31 [9106690.001]
  • [Cites] Cancer. 1997 May 1;79(9):1686-97 [9128983.001]
  • [Cites] Int J Cancer. 1997 May 16;71(4):612-9 [9178816.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):296-300 [9221808.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5201-6 [9393734.001]
  • [Cites] Glycoconj J. 1998 Feb;15(2):177-82 [9557878.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9325-30 [9689079.001]
  • [Cites] Immunity. 1998 Dec;9(6):881-90 [9881978.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):4504-12 [9988682.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):461-72 [10433939.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):24838-48 [10455156.001]
  • [Cites] Cancer Lett. 2005 Jan 10;217(1):105-13 [15596301.001]
  • [Cites] Oncogene. 2006 Jun 1;25(23):3267-76 [16418723.001]
  • [Cites] J Invest Dermatol. 2006 Sep;126(9):2065-73 [16691194.001]
  • [Cites] J Immunol. 2006 Oct 1;177(7):4742-8 [16982914.001]
  • [Cites] Int J Oncol. 2000 Feb;16(2):347-53 [10639580.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7839-53 [10713099.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11106-13 [10753916.001]
  • [Cites] APMIS. 2000 Oct;108(10):705-12 [11200826.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3352-7 [11248082.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2226-31 [11280791.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11007-15 [11118434.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3812-9 [11389021.001]
  • [Cites] APMIS. 2001 Jul-Aug;109(7-8):500-6 [11552947.001]
  • [Cites] Expert Opin Biol Ther. 2001 Mar;1(2):253-75 [11727534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2193-8 [11854515.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4063-9 [12010808.001]
  • (PMID = 19267921.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5KO8CA111829-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / E-Selectin; 0 / Polysaccharides; 0 / RNA, Messenger; EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.102 / beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-acetylglucosaminyl transferase
  • [Other-IDs] NLM/ PMC2662873
  •  go-up   go-down


98. Beattie GC, Paul I, Calvert CH: Endoscopic transanal resection of rectal tumours using a urological resectoscope--still has a role in selected patients. Colorectal Dis; 2005 Jan;7(1):47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Transanal resection of rectal villous adenomas or adenocarcinomas can be carried out using various modalities such as operative excision, fulguration, laser coagulation or cryotherapy.
  • Histopathology revealed rectal adenoma (with varying degrees of dysplasia) in 11 (55%) patients and adenocarcinoma in 9 (45%).
  • The majority (30; 70%) of resections were carried out in patients with benign disease, with 13 (30%) in patients with rectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma, Villous / surgery. Anal Canal / surgery. Proctoscopy. Rectal Neoplasms / surgery. Urologic Surgical Procedures / instrumentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606584.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Tsai BM, Finne CO, Nordenstam JF, Christoforidis D, Madoff RD, Mellgren A: Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations. Dis Colon Rectum; 2010 Jan;53(1):16-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Local recurrence rates for 121 benign and 83 malignant tumors were 5% for adenomas, 9.8% for T1 adenocarcinoma, 23.5% for T2 adenocarcinoma, 100% for T3 adenocarcinoma, and 0% for carcinoid tumors.
  • All 6 (100%) recurrent adenomas were retreated with endoscopic techniques, and 8 of 17 (47%) recurrent adenocarcinomas underwent salvage procedures with curative intent.
  • Transanal endoscopic microsurgery can be offered for (1) curative resection of benign tumors, carcinoid tumors, and select T1 adenocarcinomas, (2) histopathologic staging in indeterminate cases, and (3) palliative resection in patients medically unfit or unwilling to undergo radical resection.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Colectomy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010345.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Lee JS, Lee KT, Jung JH, Ok SW, Choi SC, Lee KH, Lee JK, Heo JS, Choi SH, Rhee JC: [Factors associated with malignancy in gallbladder polyps without gallbladder stone]. Korean J Gastroenterol; 2008 Aug;52(2):97-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical and radiological features of the polyps were compared between the two groups (neoplastic vs. non-neoplastic) and in the three groups (non-neoplastic vs. adenoma vs. adenocarcinoma).
  • RESULTS: Of 354 patients, non-neoplastic polyps were observed in 229 (64.7%) patents, adenoma in 85 (24.0%) and adenocarcinoma in 40 (11.3%).
  • The mean diameter of non-neoplastic polyp, adenoma, and adenocarcinoma were 11.3+/-2.8 mm, 16.0+/-7.2 mm, and 27.0+/-8.9 mm, respectively.
  • The mean age of patients with non-neoplastic polyp, adenoma, and adenocarcinoma were 44.8+/-11.3, 49.9+/-12.5, and 60.8+/-9.6, respectively.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Adult. Aged. Aged, 80 and over. Data Interpretation, Statistical. Female. Humans. Male. Middle Aged. Odds Ratio. Predictive Value of Tests. ROC Curve

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077501.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down






Advertisement